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The role of probiotics in allergy prevention remains uncertain but has been shown to 
have a possible protective effect on allergic diseases. Probiotics can modulate local 
and systemic immune responses, resulting in decrease in infectious disease and 
increase efficacy to vaccination. 
Objectives:  
To assess the effect of probiotic supplementation in the first 6 months of life on  
i. allergic diseases at two years of age in Asian infants at risk of allergic disease. 
ii. specific antibody response against Hepatitis B as a surrogate marker for infant 
immune response to vaccination. 
iii. protective benefit against infections. 
iv. impact on growth and safety. 
Methods:  
This double-blind, placebo-controlled randomized clinical trial involved 253 infants 
with a family history of allergic disease. Infants received at least 60ml of milk 
formula with or without probiotic (Bifidobacterium longum [BL999] 1×107 cfu/g and 
Lactobacillus rhamnosus [LPR] 2×107 cfu/g) daily for the first 6 months. Clinical 
evaluation was performed at 1, 3, 6, 12 and 24 months of age, with skin prick tests 
conducted at the 12 and 24 months. Serum samples were collected from cord blood 
and at 12 month visit to determine total immunoglobulin E and Hepatitis B virus 









Cumulative incidence of eczema in the probiotic (22%) group was similar to placebo 
(26%) at 2 years of age (adjusted odds ratio ORadj=0.73; 95% confidence interval 
CI=0.39 to 1.34). Prevalence of allergen sensitization showed no difference (18.6% vs. 
18.9% in placebo, ORadj=0.92; 95% CI= 0.46 to 1.84). No difference in the incidence 
rate of asthma (probiotic=8.9% vs placebo=9.1%, ORadj=1.15; 95% CI=0.46 to 2.87) 
and allergic rhinitis (1.61% vs. 2.48% in the placebo, p=0.86) between the two groups 
was observed. 
 
Improvement in Hepatitis B surface antibody responses in subjects receiving 
monovalent doses of Hepatitis B vaccine at 0, 1 month and a DTPa-Hepatitis B 
combination vaccine at 6 months [placebo:187.97 (180.70–195.24), probiotic:345.70 
(339.41–351.99) mIU/ml] (p=0.069) was demonstrated, but not in those who received 
3 monovalent doses [placebo:302.34 (296.31–308.37), probiotic:302.06 (296.31–
307.81) mIU/ml] (p=0.996). 
 
The rates of infections were similar. However, 3.94 times more infants were 
hospitalized due to infections during the first 6 months in the probiotic group (95% 
CI=1.21 to 12.75, p=0.022) but this difference was not observed later. Adequate 











Early life administration of a cow’s milk formula supplemented with probiotics 
showed no effect on prevention of allergic diseases in the first 2 years of life in Asian 
infants at risk of allergic disease. However, probiotics may enhance specific antibody 
responses in infants receiving certain Hepatitis B vaccine schedules. Despite increase 
hospitalization due to infections, better growth was observed in the probiotic group. 
Further work is needed to determine whether timing of supplementation, dose and 
probiotic strain are important considerations. The role and complexities of interaction 
between the early microbial environment and the developing immune system needs to 










1 Chapter 1: Introduction 
 
The increasing prevalence of allergic diseases worldwide has become a global health 
and socioeconomic burden including in Singapore [1]. For obvious reasons, effective 
strategies for the primary prevention of allergic diseases in high-risk infants with 
family history of atopy would be more attractive compared to treatment of established 
disease. 
 
Research on immune responses in early life has indicated that early childhood is a 
critical window of opportunity for intervention. During this period,  initial 
programming of immunologic memory occurs and therefore any stimulus that alters 
the functional competence of the immune system could result in the susceptibility to 
allergic sensitization and eventual development of persistent disease into adulthood 
[2]. This life phase is also a period of intensive growth and remodeling of the organs. 
Early viral or allergy-mediated inflammatory damage to these rapidly growing tissues 
can result in long-lasting changes of the allergen responder phenotype [3].  
 
Potential prevention strategies were initially based on allergen avoidance through the 
control of maternal exposure to allergens and environmental control of allergen levels 
during infancy [4]. However, these measures are not practicable over a prolonged 
period of time. A more recently devised strategy involves repeated low dose allergen 
exposure to induce immune tolerance [5]. The Global Prevention of Asthma in 
Children (GPAC) Study is double-blind, randomized, placebo-controlled study 
recruiting children between the ages of 18-30 months at 5 international study sites to 





year to explore the use of sublingual immunotherapy to promote tolerance to common 
allergens (http://www.globalasthmastudy.org).  However, such a regime has the 
potential for overstimulation of immune responses and could not be employed in early 
infancy [2].  
 
Enhancement of postnatal maturation of both the innate and adaptive immune 
functions through early stimulation by the signals of the gut microbiota provides 
another potential strategy for primary prevention. Approaches such as prebiotics and 
probiotics, microbial vaccines (in particular mycobacteria) [6] and mixed bacterial 
extracts have been evaluated. Recent experimental and epidemiological data have 
suggested that disruption of gut microbiota could drive the development of allergic 
airway response without any previous systemic priming. The ‘microflora hypothesis 
of allergic diseases’ has been postulated to highlight the role of gut microbiota in 
modulating host immunity [7]. Probiotics which are healthy bacteria of the gut are 
candidate agents proposed to provide beneficial immunoregulatory signals to 
potentially prevent the development of sensitization and allergic diseases during early 
infancy. The primary aim of this study is therefore to assess the effect of 
administration of probiotics from birth on the prevention of allergic sensitization and 
allergic diseases.  At the initiation of this clinical trial, very few randomized trials had 
been reported to evaluate the efficacy of this strategy [8].  This study was intended to 
substantiate or refute these earlier studies as well as to provide data in an Asian 
population.  
 
Attenuated immune function in atopic infants may also include reduced capacity to 





secondary aims of this study are to assess the effect of probiotic supplementation in 
the first 6 months of life on protective benefit against illnesses and immune response 
to vaccination. Safety of the probiotic administration and impact on growth of 
newborn infants are also documented in this study.  
 
1.1 Atopy and allergic diseases 
1.1.1 Definitions  
 
The standardised nomenclature of allergy was revised by the World Allergy 
Organization as an update of the European Academy of Allergy and Immunology 
Allergy Position Statement [15]. This nomenclature defines “atopy” as a “personal or 
familial tendency to become sensitized and produce immunoglobulin E (IgE) 
antibodies in response to ordinary exposures of allergens, usually proteins, and to 
develop typical symptoms of asthma, rhinoconjunctivitis, or eczema”. The term atopy 
cannot be used if IgE sensitization has not been documented by IgE antibodies in 
serum or by a positive skin prick test. 
 
Allergy is defined as a hypersensitivity reaction initiated by immunologic 
mechanisms and can be antibody-mediated or cell-mediated which is further classified 
into IgE-mediated allergy or non-IgE-mediated allergy [15].  
 
Eczema is described by Hanifin and Rajka and modified by Seymour et al. for infants 
[16] as a pruritic rash over the face and/or extensors with a chronic relapsing course. 
Similar to the classification of atopy, atopic eczema is based on IgE sensitization and 
use of the term atopic eczema should be associated with the documentation of a 





The epidemiological definition of clinical asthma involves three episodes of nocturnal 
cough with sleep disturbances or wheezing, separated by at least seven days, in a 
setting where asthma is likely and conditions other than allergy have been excluded 
[17]. Asthma is a complex chronic disorder of the airways and is required to be 
clinically diagnosed in the presence of variable and recurring symptoms, airflow 
obstruction, bronchial hyperresponsiveness, and an underlying inflammation [18]. 
Thus making a diagnosis of asthma in young infants in our study had been difficult 
due to episodic respiratory symptoms such as wheezing and cough which were 
symptoms of recurrent respiratory tract infections. Allergic rhinitis will be diagnosed 
if the child has rhinorrhea, nasal obstruction, nasal itching and sneezing which are 
reversible spontaneously or with treatment that is not due to a respiratory infection as 
per recommendations from the World Health Organization (WHO) Allergic Rhinitis 
and its Impact on Asthma workshop (ARIA) [19]. Despite its high prevalence, allergic 
rhinitis is often undiagnosed in young children as children lack the ability to verbalize 
their symptoms and the parents underreported the symptoms as common cold or flu.  
 
1.1.2 Epidemiology of Allergic Diseases in Childhood 
 
The International Study of Asthma and Allergies in Childhood (ISAAC) was 
conducted in three phases since 1991 to describe the prevalence and severity of 
asthma, rhinitis and eczema in children living in different countries. In the most recent 
Phase III study conducted worldwide between 2002 and 2003 in children aged 6-7 
years and 13-14 years, the rise in prevalence of symptoms in many centres has been 
found to be concerning [20]. Wide global variations exist with the prevalence of 
current wheeze ranging from 0.8% in Tibet, China to 32.6% in Wellington, New 





Rica in the 6-7 year olds [21]. Similarly the prevalence of current rhinoconjunctivitis 
symptoms ranged from 1.0% in Davangere, India to 45.1% in Asunciόn, Paraguay in 
the 13-14 years old children, and from 4.2% in the Indian Sub-Continent to 12.7% in 
Latin America in the 6-7 year olds. Co-morbidity with asthma and eczema varied 
from 1.6% in the Indian sub-continent to 4.7% in North America. [22].  
 
In Singapore, the ISAAC Phase I written questionnaire was administered to 6-7 years 
old (n=2030) and 12-15 years old (n=4208) schoolchildren  in 1994 [23]. The overall 
prevalence of current wheeze was 12% with prevalence of doctor diagnosed asthma as 
20%. In general, current rhinitis was reported by 37.1% and eczema was the least 
commonly reported with 9.4% having current symptoms. Allergic disorders were 
found to be common in Singapore and an increasing problem not only in the West but 
also in an Asian population. By comparing the data from phase I and phase III of the 
ISAAC surveys conducted in Singapore seven years later in 2001, the prevalence of 
current wheeze decreased significantly in the 6–7 year age group from 16.6% to 
10.2% (p<0.001) but increased slightly in the 12–15 year age group from 9.9% in 
1994 to 11.9% (p=0.015) in 2001. Rhinitis showed increasing severity of symptoms in 
both age groups and the prevalence of children diagnosed with eczema showed a 
significant increase from 3.0% to 8.8% (p<0.001) in the 6-7 years old group [1]. 
Furthermore, the prevalence of children who have had more than one atopic disorder 
increased significantly from 6.0% in 1994 to 10.2% in 2001 (p < 0.001) [24]. 
 
1.1.3 Immunological basis of atopy and allergic diseases 
 
According to the classic type 1 (Th1) / type 2 helper T (Th2) cells paradigm theory, 





prior to microbial exposure. Generation of the Th2-type cytokines, including 
interleukin-4 (IL-4), IL-5 and IL-13 promote IgE production and eosinophilia. This 
hygiene hypothesis suggested by Strachan [25] indicated that a decrease in the 
microbial load due to clean living environments, antibiotic use and hygienic food 
standards lead to decreased microbial exposure in early life resulting in an over-
expression of the allergic response. There has been much clinical evidence to support 
this hypothesis. An inverse relationship between infections, including mycobacteria, 
measles and hepatitis A virus, early in life and atopy have been suggested [26].  Early 
entry to nurseries [27], greater sib ship numbers [28], living on farms [29] and early 
gastrointestinal infections [30] are all proposed to be associated with decreased 
incidence of atopy. These conditions are associated with increased microbial pressure 
early in life. Endotoxin stimulates antigen-presenting cells to produce IL-12 which 
triggers the development of antigen-specific Th1 cells and inhibits Th2 cells.  
 
However, this rigid Th1/Th2 paradigm cannot explain the Th1 type inflammation 
response elicited in chronic atopic eczema and asthma. Furthermore, Th1-mediated 
autoimmune disease often coexist with Th2-mediated atopic disease [31]. 
Consequently, an extended version of the hygiene hypothesis of atopic disease has 
been introduced. Several subsets of CD4+ cells are capable of suppressive 
mechanisms to control immune responses against both self-antigens and allergens in 
autoimmune and atopic diseases respectively. These regulatory T (Treg) cells inhibit 
both Th1 and Th2 cells development in vitro. It has further been suggested that the 
lack of microbial stimulation affects the development of Treg cells, resulting in an 
atopic phenotype [32]. Allergic patients have been found to have very low IL-10-





10-secreting T regulatory type 1 (Tr1) cells secrete high levels of IL-10 and 
transforming growth factor-beta (TGF-β) which can serve to suppress both allergy 
and autoimmune diseases [34].  
 
There are namely 4 main types of T-cells that regulate one other. The Th1 cells 
promote cytokine IL-12 to inhibit Th2 cell development, whereas the Th2 cells 
produce IL-4 to blocks Th1 cell development. The Th1 derived interferon-gamma 
(IFN-γ) on the other hand, blocks Th17 cell development and prevents IL-17 
mediated inflammation in autoimmune murine models [35, 36]. In healthy human 
individuals, there are less than 1% of Th17 cells in the peripheral blood, but in 
patients with Crohn’s disease, there are slightly higher proportion of Th17 among the 
CD4+ T cells [37]. IL-17A messenger RNA in sputum has also been found to be 
significantly higher in asthma patients [38] with the evidence that IL-17 can 
contributes to the development of allergen-induced airway hyperresponsiveness and 
airway remodelling [39]. The Treg cells inhibit the development of both Th1 and Th2 
cells by direct contact-dependent mechanisms, IL-10 and TGF-β. Onset of allergic 
diseases may be determined by the ratio of proinflammatory T-cell subsets versus Treg 
subsets. In chronic allergic diseases, Th17 and tumour necrosis factor-alpha (TNF-α) 
rich inflammatory Th2 cells can be upregulated while in asymptomatic atopic 














Figure 1-1 Onset of allergic diseases may be determined by the ratio of Th17 and Th2 
versus Treg subsets. In patients with chronic allergic diseases, proinflammatory T-cell 
subsets, namely Th17 cells and Th2 cells, that are capable of producing high levels of 




1.1.4 The microflora hypothesis of allergic disease 
 
The role of the indigenous intestinal microbiota has further been proposed to 
potentially outweigh that of infections in immune maturation. The most common 
anaerobes within the gastrointestinal microbiota are Bacteroides, Bifidobacterium, 
Eubacterium, Fusobacterium, Clostridium and Lactobacillus. Other facultative 
anaerobes such as Escherichia coli and Enterococcus are also present. Intestinal 
colonization begins rapidly in the newborn and microbial succession establishes with 
age in the first year of life until an adult-type highly complex microbiota composition 
has been achieved. Bifidobacterium, Clostridium and Bacteroides are among the first 
anaerobes colonizing the gut [41]. It has been suggested that antibiotic use and dietary 
changes in affluent countries have disrupted the role of endogenous microbiota in 
maintaining mucosal immunological tolerance [7]. Differences in intestinal microflora 





in babies who are breast fed compared to formula fed babies. Breastfeeding promotes 
bifidobacteria and lactobacilli colonization that inhibit growth of pathogens [42]. 
Vaginally delivered babies are colonized with bifidobacteria and lactobacilli earlier 
than caesarean-delivered babies [43, 44]. Furthermore, children born by means of 
caesarean section was found to be associated with an increased risk of developing 
respiratory allergies [45].  
 
A mouse model of antibiotic-induced gastrointestinal microbiota disruption resulted 
in the development of an allergic airway response to subsequent mould spore 
(Aspergillus fumigatus) exposure in immunocompetent C57BL/6 mice without 
previous systemic antigen priming. Levels of eosinophils, mast cells, lung leukocyte 
IL-5, IL-13, IFN-γ, total serum Ig E, and mucus-secreting cells were significantly 
increased in the microbiota disrupted mice [46]. Similarly in BALB/c mice, 
antibiotic-induced microbiota disruption promoted the same airway allergic response 
upon subsequent challenge with mould spores or ovalbumin (OVA) but not in mice 
with normal microbiota [47]. 
 
The same association between altered faecal microbiota and allergic disease has been 
shown in industrialized and developing countries with a high (Sweden) and a low 
(Estonia) prevalence of allergy respectively. In both countries, allergic children were 
colonized with higher levels of aerobic microbes and lower levels of anaerobic 
microbes, particularly lactobacilli [48]. It is further noted that infants that eventually 
developed allergies at 2 years of life were colonized with decreased levels of 
Enterococcus species at the age of 1 month and Bifidobacteria through the first year 





differences in gut microflora composition between allergic and nonallergic infants can 
be observed preceding the manifestation of allergies very early in life. Likewise, 
another prospective epidemiological study demonstrated that infants with atopic 
sensitization harboured different bacterial cellular fatty acid profile with more 
clostridia and less bifidobacteria in their stools at 3 weeks of age as compared to non-
atopic infants [50].  
 
A case-control study of atopic dermatitis children with age- and sex-matched healthy 
controls similarly found lower levels of Bifidobacterium species in the faecal 
specimens of patients with eczema. Further, Bifidobacterium species were 
significantly lower in patients with more severe skin symptoms, suggesting a “dose-
response” relationship [51]. This finding was further substantiated by another case-
control study conducted in Singapore where the eczematous subjects similarly 
harboured lower counts of Bifidobacterium. In this study, higher Clostridium and 
lactic acid bacteria count were also observed [52]. These results are supported by 
conventional bacterial cultivation and improved culture-independent molecular 
methods used on targeting different species in the studies. In addition, children with 
atopic eczema have further been revealed to have predominantly Bifidobacterium 
adolescentis while healthy infants harboured more Bifidobacterium bifidum [53]. This 
difference in microbiota composition might be attributed by reduced adhesive abilities 
of bifidobacteria to the intestinal mucus in allergic infants [54]. Bifidobacteria from 
allergic infants induce less IL-10 production but more proinflammatory cytokine in 
vitro eliciting a Th1 type immune response  [55].  These data support the microflora 
hypothesis of allergic disease that the differences in gut microbiota play an influential 





mechanisms against atopy. This hypothesis paves the way for the use of probiotics 




Probiotics in the form of fermented dairy products such as yoghurt and drinks have 
been consumed by humans for thousands of years and in recent times, freeze-dried 
bacteria in capsules have become popular dietary supplements. According to Food 
and Agriculture Organization (FAO) / World Health Organization (WHO) expert 
panel guidelines, probiotics are defined as live microorganisms which when 
administered in adequate amounts confer a health benefit on the host [56]. The genus 
and species of a probiotic can have differential effects thus the strain identity is 
important to relate the probiotic strain to specific health effects. Strains of 
Bifidobacterium and Lactobacillus species, which are the most widely used, are 
indigenous to the human gut and are resistant to gastric acid digestion to remain 
viable and adhere to the intestinal epithelium [57, 58]. Majority of the probiotics in 
food are lactic acid bacteria (LAB) which are generally gram-positive, non spore-
forming organisms that are devoid of catalase enzyme and are aerotolerant to produce 
lactic acid during sugar fermentation [59]. Species from other bacterial genera such as 
Streptococcus and Enterococcus and yeasts from the genus Saccharomyces have also 
been considered as probiotics [60]. The common probiotics used in dairy products 
such as Lactobacillus acidophilus, Lactobacillus casei and Bifidobacteria are listed in 
Table 1-1.  
Apart from using probiotics alone, combination of probiotics and prebiotics has been 
added to milk and nutritional supplements. This combination is known as synbiotics. 





selectively stimulating the growth or metabolic activity of beneficial intestinal 
microbiota and reduce the growth of pathogens [61]. Increasing the intake of 
prebiotics (commonly oligosaccharides) by supplementation to infant feeds has the 
potential to prevent allergic diseases in infants by modulating the immune system [62, 
63].  
 
Table 1-1 Common probiotics associated with dairy products 
 
Lactobacillus acidophilus group - L. acidophilus 
- L. amylovorus 
- L. crispatus 
- L. gasseri 
- L. johnsonni 
Lactobacillus casei group - L. casei 
- L. paracasei 
- L. rhamnosus 
Lactobacillus reuteri  
Lactobacillus plantarum  
Bifidobacterium species - B. lactis 
- B. longum 
- B. adolescentis 
- B. animalis 
- B. bifidum 
- B. breve 
- B. infantis 
 
1.3 Immunomodulatory effects of probiotics 
 
Studies that demonstrate the efficacy of probiotics is rapidly increasing and one area 
of particular interest is the effect of administration of probiotics on immune response. 
Probiotics are promising immunomodulators which enhance both the innate and 
adaptive immunities in the host [64] as they adhere to epithelial cells and proliferate 
in the mucosa stimulating the gut immune responses. The gut immune system, which 
consists of the gut-associated lymphoid tissue (GALT), mucosal lamina propria and 
the epithelium, protects us against pathogens and also induces tolerance to harmless 
food and microbial antigens. The intestinal microbiota acts as a microbial stimulation 
to influence systemic and mucosal immunity and importantly, microbial load acquired 





interaction provides antigenic challenge and aids in the maturation of the mucosal 
barrier mechanisms and the immune system.  
 
1.3.1 Local effects on gut epithelium 
 
Effect of Lactobacillus rhamnosus GG has been observed in several studies. The 
mitogenic effect of L. rhamnosus GG in germ-free rats resulted in increase of cell 
production contributing to faster mucosal regeneration [67]. This could act as a wash-
out mechanism for pathogenic microbes. Furthermore, L. rhamnosus GG was 
observed to stabilize the mucosal barrier and reverse gut permeability disorder when 
suckling rats were challenged with cow’s milk [68]. This reduced systemic antigen 
load by maintaining the integrity of the intestinal barrier. In addition, Yan et al. 
reported the increase survival of intestinal cells in the presence of L. rhamnosus GG 
through the prevention of cytokine-induced apoptosis which may be protecting the 
epithelial cells against inflammation-induced injury [69]. 
 
1.3.2 Probiotics and the innate immune system  
 
Both live and heat-killed probiotics and the components of probiotic bacteria have 
been shown to stimulate the innate immune system. L. acidophilus and L.casei 
enhanced the phagocytosis capacity of murine peritoneal macrophages [70]. It is 
further demonstrated in clinical trials that L.acidophilus La1 increased phagocytosis 
of human leucocytes [71-73]. Other probiotics, namely Bifidobacterium lactis Bb12 
[72], B. lactis HN019 [74] also increased phagocytosis considerably. However, the 
effect of probiotics in healthy subjects and patients with milk hypersensitivity has 





neutrophil activation through upregulation of receptors (CR1. CR3, FcγRIII and FcαR) 
in healthy individuals but down-regulated immunoinflammatory response by 
inhibiting phagocytosis in allergic patients [75].  
 
Lactobacilli could enhance antigen presentation of dendritic cells as killed 
Lactobacillus species upregulated MHC class II and CD86 in murine. L casei further 
induced IL-12, IL-6 and TNF-α while L. reuteri inhibited activities of L.casei [76]. 
The differential regulation suggested that the composition of the gut microflora can 
modify immune response.  
 
Cytokines produced following the interaction of probiotics with the intestinal 
epithelium plays an important role in the immunomodulatory activity. A significant 
involvement of toll-like receptors (TLR), including TLR9 [77] and possibly TLR2 
and TLR4 expressed on enterocytes contributes to the anti-inflammatory effects of 
probiotics. In addition, enterocytes produce IL-8 and IL-6 in the presence of probiotic 
organisms. Adhesion between live L. plantarum 299v and HT-29 epithelial cells, 
which were previously stimulated by TNF-α to induce inflammation, increased the 
IL-8 mRNA levels in the cells to recruit neutrophils [78]. B. lactis Bb12 [79], L. casei 
CRL 431 and L. helveticus R389 [80] increased IL-6 secretion in murine models. The 
data suggested that different species of probiotics would have differential responses 
with regards to the innate immune system and impact the level of cytokine production.  
 
1.3.3 Probiotics and the adaptive immune system  






Probiotics also influence IgA production. Mice fed with yogurt supplemented with L. 
acidophilus and Bifidobacterium species enhanced both mucosal and systemic IgA 
responses to cholera toxin [81]. L. rhamnosus GG enhanced circulating IgA secreting 
cell response in acute rotavirus-induced diarrhoea patients [82]. In children with 
Crohn’s disease, L. rhamnosus GG increased IgA production to cow milk β-
lactoglobulin [83]. The effect of probiotics to enhance humoral immune responses to 
vaccinations has also been evaluated.  
 
1.3.3.1.1 Effects of probiotics on oral vaccination 
 
There is increasing evidence which support potential influences of probiotics on 
immunological responses to vaccines. Immunological response both to oral and 
parenteral vaccines have been evaluated with probiotic supplementation. . Gnotobiotic 
animal models have shown that probiotic has a significant immunostimulating effect 
on the local and systemic immune responses with increased specific IFNγ in ileum 
and spleen, IgA and IgG in ileum, and serum IgM, IgA and IgG antibody in oral 
rotavirus vaccinated pigs with L. acidophilus colonization [84]. Another gnotobiotic 
pigs study suggested that L. acidophilus and L. reuteri colonization reduced the 
distribution and frequencies of monocytes/macrophages and dendritic cells in ileum, 
spleen and blood due to human rotavirus infection [85].  
 
Probiotic have been shown to enhance humoral immune responses to oral 
immunization such as that of rotavirus [86], Salmonella [87, 88], polio [89, 90] and 
cholera [91] in double-blind, randomized, controlled studies summarized in Table 1.2.  
Oral administration of L. rhamnosus GG with live oral rotavirus vaccine in 2 to 5 





cells from 29% in placebo to 79% in probiotic group (p=0.02) indicating an early 
humoral immune response to rotavirus infection. Furthermore, IgA seroconversion 
increased from 74% in infants who received placebo to 93% in the probiotic group 
(p=0.05) [86].  
 
In another study, healthy human volunteers received either L. rhamnosus GG, 
Lactococcus lactis or placebo with an attenuated Salmonella typhi Ty21a oral vaccine. 
Although the IgA-, IgG- and IgM-secreting cells were found to be similar but there 
was a trend towards a higher IgA specific anti-S. typhi Ty21a secreting cells among 
the subjects who received the vaccine with L. rhamnosus GG. In addition, subjects 
who received L. lactis showed significantly higher CR3 receptor expression on 
neutrophils in peripheral blood than those receiving either the placebo or L. 
rhamnosus GG. This suggests that L. lactis could influence phagocytosis and affect 
the non-specific immune response although it did not enhance specific immune 
responses [87]. The effects of probiotics appear to be strain specific and may be 
determined by the colonizing properties of the organism. Moreover, administration of 
probiotics in fermented milk in conjunction with the vaccine could further enhance 
the immunomodulatory effect of probiotic as milk acts as a carrier to ensure large 
numbers of viable cells survive the passage through the harsh environment of the 
gastrointestinal tract. This has been observed in healthy adult subjects who consumed 
fermented milk containing L. acidophilus Lal and bifidobacteria with the 
administration of an attenuated Salmonella typhi Ty21a. The specific serum IgA to S. 
typhi Ty21a in the probiotics group was twice that of the control group (p=0.04). Both 
specific humoral immune response and systemic immune effect were observed as the 






Efficacy of oral polio vaccination was also found to be enhanced in 2 studies. In a 
double-blind, randomized, controlled study, subjects consumed acidified milk 
products either with L. rhamnosus GG or L. acidophilus CRL431 or placebo. Subjects 
were vaccinated orally against polio 1, 2 and 3 in the second week of the study. Both 
probiotics increased poliovirus neutralizing antibody titres to a maximum of 2 fold 
and markedly enhanced poliovirus serotype-1-specific IgA. L. rhamnosus GG, in 
particular, increased the IgA titre to 3.9 fold (p<0.036). It also increased poliovirus 
serotype-1-specific IgG by 2.2 fold [89]. These results were substantiated in another 
study whereby consumption of cow milk-based follow-up formula containing viable B. 
lactis Bb-12 after routine oral polio immunization significantly increased faecal levels 
of total IgA to a peak level of 2.9-fold (p<0.05) with a increasing trend of anti-
poliovirus IgA during consumption when compared to prior consumption. The total 
IgA levels however decreased to the initial levels after cessation of formula intake 
[90].  
 
The immunomodulatory effect of probiotics was also evaluated in oral cholera 
vaccination study with 7 strains of Lactobacillus or Bifidobacterium [91]. Probiotics 
were supplemented for 21 days and oral cholera vaccination occurred at day 7 and day 
14 after the start of supplementation. Specific salivary IgA analysis showed no 
difference between groups. Serum IgG increased in 2 probiotic groups, namely B. 
lactis Bl-04 and L. acidophilus La-14, 7 days after second vaccine administration 
(p=0.01). In contrast, L. acidophilus La-14 was found to decrease serum IgA. This 
change may be due to the concomitant increase of serum IgG in this group. Out of the 





serum concentrations with varying effects compared with controls (p < 0.1), although 
overall vaccination titre was not altered. Strain-specific effects of probiotics were 
noted as different strains of L. acidophilus exhibited different effects and this 





Table 1-2  Summary of clinical trials evaluating effects of probiotics on oral vaccination 
 
Study No. of Subjects   Age 
Range 
(mean) 
Probiotic Dose Supplement 
period 





et al., 1995 
[86] 
 
Probiotic = 30 
 




  (4.1) 
 
L. rhamnosus GG 
 






• Increase specific IgM 
secreting cells from 29% in 
placebo to 79% in 
probiotic (p=0.02) 
• IgA seroconversion 
increased 74% to 93% in 
















(1) L. rhamnosus GG 
 
(2) Lactococcus lactis  
 
(1) 4 x 1010 CFU 
      daily 
(2) 3.4 x 1010 CFU 







• IgA-, IgG- and IgM-
secreting cells similar  
• Trend towards higher IgA 
specific anti-S. typhi Ty21a 
secreting cells in L. 
rhamnosus GG group 
• Higher CR3 receptor 
expression on neutrophils 





et al., 1994 
[88] 
 
Probiotic = 16 
 






L. acidophilus La1 and 
bifidobacteria 
 







• specific IgA to S. typhi 
Ty21a doubled in probiotic 
group (p=0.04) 
• total serum IgA enhanced 





Table 1.2  Summary of clinical trials evaluating effects of probiotics on oral vaccination (continued) 
 
Study No. of Subjects   Age 
Range 
(mean) 
Probiotic Dose Supplement 
period 
Vaccination Effect of probiotic on  
Outcome measures 
 
de Vrese  








(1) L. rhamnosus GG 
(2) L. acidophilus 
CRL431 
1010 CFU/100g in 
yoghurt daily 
5 weeks Polio  • Neutralizing antibody titres 
increase to a max. of 2 fold  
• Enhanced serotype-1-
specific IgA. L. rhamnosus 
GG, to 3.9 fold (p<0.036).  
• Increased serotype-1-
specific IgG by 2.2 fold 
Fukushima 
et al., 1998 
[90] 
Probiotic = 7  





109 CFU in milk 
daily 
21 days Polio • Faecal levels of total IgA 
increase to 2.9-fold 














(1) B. lactis Bi-07 
(2) B. lactis Bl-04 
(3) L. acidophilus La-
14 




(6) L. paracasei Lpc-
37 
(7) L. salivarius Ls-33 
 
 





• Specific salivary no change 
• Serum IgG increased in B. 
lactis Bl-04 (day 0-21) 
(p=0.01) 
• Decrease serum IgA in L. 
acidophilus La-14  (day 0-
21) (p=0.09), and day 21-
28 (p=0.05).  
• Increased serum IgA in L. 
acidophilus NCFM® (day 
21-28) (p = 0.09) 






1.3.3.1.2 Effects of probiotics on parenteral vaccination 
 
Apart from oral vaccinations, the effects of probiotic on antibody responses to 
diphtheria, tetanus, Haemophilus influenzae type b (Hib) and influenza parenteral 
vaccination [93-97] have also been evaluated and probiotic has been proposed as 
vaccines adjuvant (Table 1.3).  
 
In a randomized double-blind placebo-controlled study by Kukkonen et al. [93], 
probiotics supplementation in allergy-prone infants improved immune response to 
Hib immunization as the geometric mean Hib IgG concentration was higher and there 
were 2-fold more subjects with protective Hib antibody concentration in the probiotic 
group than that of control (p=0.02). Diptheria and tetanus IgG antibody 
concentrations however showed no difference between the groups.  
 
Supplementation of Bifidobacterium breve strain C50 in milk from birth to 4 months 
old was also found to increase antipoliovirus IgA titers significantly (p <0.02) as 
compared to that of subjects in placebo group. This antibody titers correlated with 
bifidobacteria, especially B. longum/B. infantis and B. breve levels in the stools (p 
<0.002) [94]. Furthermore, oral administration of L. fermentum CECT5716 increased 
the immunologic response to an anti-influenza vaccine and lowered the incidence of 
influenza-like illness 5 months after vaccination by increasing the antigen specific Ig 
A. The number of natural killer (NK) cells and TNF-α level in serum were higher in 
the probiotic group compared to the placebo. [95].  
 
Another study performed in infants that received L. acidophilus in the first six months 





placebo group (p=0.03). Although this effect cannot be directly extrapolated to effects 
on vaccine responses, the author concluded that probiotics may have 
immunomodulatory effects on vaccine responses which needs to be determined in 
further studies [96]. 
 
The most recent study conducted by West et al. [97] investigated the impact of L. 
paracasei subspecies paracasei strain F19 during weaning on infants who received 
DTaP (diphtheria and tetanus toxoid and acellular pertussis), polio and Hib-conjugate 
vaccines. Probiotics supplementation increased the capacity to raise the IgG anti-
diphtheria immune response with more marked effects after adjusting for infants who 
were breastfed for less than 6 months in the 4 week after the second vaccination dose 
(p = 0.018) and prior to the third dose (p =0.048). This similar trend was observed for 
the specific IgG antibody concentrations to tetanus toxoid after adjusting for 
breastfeeding duration and probiotic colonization. In contrast, there was no effect of 
probiotic supplementation on the immune response to the Hib polysaccharide antigen.  
 
In conclusion, there are only a few studies that have looked at the effects of probiotics 
on different vaccination responses. The efficacy and clinical relevance requires 











Table 1-3  Summary of clinical trials evaluating effects of probiotics on parenteral vaccination  
 
Study No. of Subjects   Age 
Range 
(mean) 
Probiotic Dose Supplement 
period 













Mixture of 4 strains 
with prebiotic galacto-
oligosaccharides 
1. LGG and  
2. L rhamnosus LC705 
3. Bifidobacterium 

























pertussis) at 3,4,5 
mo and 
Haemophilus 
influenza type b 
(Hib) at 4 mo 
• Frequency of Hib antibody 
conc. (≥1 μg /ml) doubled  (p 
= 0.02) 
• Hib IgG concentration higher 
0.75 (0.15-2.71) μg/ml than 
in placebo 0.40 (0.15-0.92) 
μg /ml (p = 0.064).  






























at 2, 3, and 4 mo 
• Fecal bifidobacterial level 
higher at 4 mo (p=0.0498) 
• B. longum/B. infantis carriage 
higher at 4 months 
(p=0.0399).  
• Antipoliovirus IgA titers 
increased significantly (p 
<0.02).  
• Antibody titers correlated 
with bifidobacteria, especially 
B. longum/B. infantis and B. 
breve levels (p <0.002). 
• Presence of B. longum/B. 
infantis correlated with higher 
levels of antipoliovirus IgA 





Table 1.3  Summary of clinical trials evaluating effects of probiotics on parenteral vaccination (continued) 
 
Study No. of Subjects   Age 
Range 
(mean) 
Probiotic Dose Supplement 
period 




et al., 2007 
[95] 
Probiotic = 25 






1x 1010 CFU 
daily 
28 days Influenza • Increase natural killer cells  
• Significant increase in 
antigen specific Ig A  
• Incidence of influenza-like 
illness during 5 mo after 




Probiotic = 58 
Placebo = 60 
At 
birth 
L. acidophilus  
LAVRI-A1 
3 x 109 CFU 
daily 
6 months Tetanus toxoid • lower IL-10 responses to 
tetanus toxoid vaccine 
antigen compared with the 
placebo group (p=0.03) 
• no significant effects of 
probiotics on either Th1/Th2 
cell responses to allergens  






L. paracasei ssp. 
paracasei strain F19 
At least  
1 x 108 
CFU/serving 
of cereals 





polio and  
Hib-conjugate 
vaccines 
• Increase IgG anti- diphtheria -
> adjusting for infants 
breastfed < 6 months , 4 week 
after 2nd vaccination (p = 
0.018) and prior 3rd dose (p 
=0.048).  
• Similar trend for IgG anti-
tetanus after adjusting for 
breastfeeding duration and 
probiotic colonization. 
•  No effect on immune 






1.3.3.2  Effect of probiotics on T lymphocytes  
 
Probiotic supplementation can induce Treg cells which bear TGF-β and production of 
regulatory cytokines IL-10. L. reuteri and L. casei influenced monocyte-derived 
dendritic cells to instruct naïve CD4+ T cells to differentiate into Treg cells which 
produced increased levels of IL-10 in vitro. However, L. plantarum, which did not 
bind to the lectin dendritic cell, was unable to induce Treg cell differentiation [98]. L. 
paracasei NCC2461 was shown in another in vitro study to induce the development 
of a CD4+ T cell subset with immunoregulatory properties that secrete high IL-10 and 
TGF- β [99] to inhibit the development of bystander T cells and reduces both the Th1 
and Th2 cells cytokines, including IFN-γ, IL-4 and IL-5 secretion.  
 
The capability of probiotics to alter the Th1 and Th2 balance has been shown in 
various studies. Different probiotic strains can have different capacities to drive pro-
inflammatory effect towards Th1 development or anti-inflammatory effect towards 
Th2 development or even stimulate both Th1 and Th2 responses. Skewing of the 
immune response towards Th1 has been shown by the administration of L. rhamnosus 
GG in children who were allergic to cow’s milk resulting in increased production of 
IFN-γ in peripheral blood mononuclear cells (PBMC) and suppressed secretion of IL-
4 [100]. Another study further indicated that L. rhamnosus GG degrades cow’s milk 
caseins which down-regulated the IL-4 production to provide protection from dietary 
antigens [101]. Other probiotic strains such as L. brevis subsp. coagulans and B. lactis 
HN019 stimulate the production of immunostimulatory cytokines such as IFN-α [74, 
102]. On the other hand, reduced production of the pro-inflammatory cytokines Il-12, 
IFN-γ and TNF- α by splenocytes and Peyer’s patches was observed when IL-10 





with L. salivarius and B. infantis. This reduction in Th1 cytokines significantly 
prevented colitis in this murine model. [103]. Subcutaneous injection of   L. salivarius 
118 can also interestingly reduce the production of pro-inflammatory Th1 cytokines 
in intestinal inflammation murine models, suggesting that the oral route may not be 
essential for probiotic to demonstrate its anti-inflammatory function [104]. Other 
probiotics have been found to stimulate both Th1 and Th2 response under different 
physiological conditions. L. rhamnosus HNOO1 in particular raised mixed 
lymphocyte cytokine production with increased IFN-γ and at the same time enhanced 
IL-4 and IL-5 production in mice during antigen sensitization [105].  
 
1.4 Clinical benefits of probiotics  
1.4.1 Potential benefits from probiotics 
 
To date, potential results have been observed for use of probiotics in the prevention 
and treatment of gastrointestinal disorders. The evidences for probiotics in the 
treatment of diarrhoea have been strong. There are more than 10 studies that have 
investigated the use of probiotics to treat or prevent acute infectious diarrhoea in both 
children and adult [106-120]. Positive results have been shown for use with L. 
rhamnosus GG [107-109, 111, 117], L. reuteri [115, 119], Saccharomyces boulardii 
[118] and other mixtures including L. acidophilus [120]. Most of these patients had 
shorter duration of symptoms and decreased severity with a decreased likelihood of 
persistent diarrhoea. Meta-analysis further substantiates the efficacy of L. rhamnosus 
GG and S. boulardii in the prevention of adverse intestinal effects of antibiotic-
associated diarrhoea in children [121]. In other studies, significant lower number of 
adult patients who received antibiotic treatment experienced nausea and diarrhoea 





In addition, probiotics have shown promising results in the treatment and prevention 
of relapses of inflammatory bowel disease. Although results have been variable in the 
small number of studies, VSL#3 has been reported as effective and recommended for 
the maintenance of remission of pouchitis [124-126]. Beneficial effects of 
Bifidobacterium infantis to relieve symptoms of irritable bowel syndrome have further 
been reported in large, randomized controlled trials [127, 128].  
 
Limited studies have been performed to propose potential applications of probiotics in 
other diseases and conditions. The use of probiotics to prevent enterocolitis has been 
promising in small studies but insufficient information is available to make a 
concluding recommendation [129]. Similarly, VSL#3 [130, 131] and L. acidophilus 
[132]  have been shown to be effective in prevention of radiation enteritis but further 
studies will be necessary. Evidence is also rapidly accumulating on the use of L. 
rhamnosus GG [133], L. reuteri [133, 134] and L. acidophilus [135] in the treatment 
of vaginitis and vaginosis which has produced impressive results in controlled trials.  
 
1.4.2 Probiotics for the treatment of allergic disease  
 
A better understanding of the potential of probiotics as preventive and therapeutic 
agent has been explored in randomized controlled trials. There have been several 
studies examining the use of probiotics to treat atopic diseases especially in the 
treatment of eczema (Table 1.4). Most of these studies classify the severity of eczema 
based on the SCORing Atopic Dermatitis (SCORAD) index established by the 
European Task Force on Atopic Dermatitis which combines objective measures such 





loss [136]. Based on the SCORAD score, the patients can be generally classified as 
having mild (<25), moderate (25-50) or severe (>50) eczema (Refer to Appendix E).  
 
The first study was conducted in 1997 by Majamaa and Isolauri [137] with 27 infants 
aged 2.5-15.7 months old fed with 5 x 108 colony-forming unit (CFU)/g L. 
rhamnnosus GG fortified extensively hydrolyzed whey formula. The subjects in both 
the probiotic and placebo group had mild/moderate eczema with baseline SCORAD 
of 26(17-38) and 21(14-31) respectively. Median SCORAD score improved 
significantly (p=0.008) from 26 to 15 in the probiotic group but not in the placebo 
group after one month. Furthermore, faecal α1- antitrypsin and TNF-α concentration 
which are markers of intestinal inflammation decreased significantly after dietary 
intervention.  
 
In a second study by the same group, exclusively breastfed infants with 
mild/moderate eczema were randomized to extensively hydrolysed whey formula, 
formula with either 3 x 108 CFU/g L. rhamnnosus GG or formula with 1 x 109 CFU/g 
B. lactis Bb-12 [138]. There were 9 subjects in each group. After 2 months 
supplementation, both the L. rhamnnosus GG and B. lactis Bb-12 treated group 
showed significant improvement of the median SCORAD score from 14 to 1 and 12 
to 0 respectively, compared to placebo 10 to 13.4 (p=0.002).  Significant decrease in 
serum soluble CD4 and urinary eosinophilic protein X were also observed in both 
probiotic supplemented group while TGFβ1 was significantly decreased in the B. 
lactis Bb-12 treated group, indicating that the control of inflammation extend beyond 






This study team further investigated the efficacy of 1 x 109 CFU/g viable and heat-
inactivated L. rhamnnosus GG in extensively hydrolyzed whey formula for the 
management of atopic eczema [139]. However, this study was terminated early due to 
adverse diarrhoea suffered by infants in the heat-inactivated probiotic group. 
Although the length of treatment had a great variation from less than a week to more 
than 10 months, significant decrease in mean SCORAD were noted in all the groups 
from 13 to 8 in the placebo group, 19 to 5 in the viable probiotic group and 15 to 7 in 
the heat inactivated probiotic group. This mean decrease in SCORAD was 
significantly higher in the viable L. rhamnosus GG treated group than in the placebo 
group (p=0.02). Presence of some bifidobacteria, lactobacilli, Bacteroides, 
enterococci and clostridia in the faeces were not significantly different before and 
after treatment in each of the 3 groups when detected with 16S rRNA-specific probes.  
 
Other studies conducted with various strains of lactobacilli further support the 
favourable effects of probiotics on atopic eczema. In a randomized placebo controlled 
cross-over trial, 43 moderate/severe eczematous children with a wide age group of 1 
to 13 years old were given 1 x 1010 CFU L. rhamnosus 19070-2 and L. reuteri DSM 
122460 each twice daily in water [140]. This cross-over trial was conducted with 6 
weeks treatment or placebo and a 6 weeks wash-out period in between. Although no 
overall significant change in total SCORAD after treatment with probiotics was 
observed in this cross-over study, a minor improvement of 2.4 SCORAD score was 
found in the IgE-sensitized group compared to a 3.2 points worsening in the placebo 
group, however this difference was not clinically significant. The wide age range, 





before treatment could have contributed to the reduced efficacy of probiotics in this 
study.   
 
To date, the largest randomized double blind placebo-controlled trial of the effects of 
probiotics on treatment of eczema is that of Viljanen et al. [141] on 230 infants with 
suspected cow's milk allergy. The infants were randomized to either 5 x 109 CFU L. 
rhamnosus GG or a mixture of 4 probiotics, namely 5x 109 CFU L. rhamnosus GG, 
5x 109 CFU L rhamnosus LC705, 2 x 108 CFU B. breve Bbi99 and 2 x 109 CFU 
Propionibacterium freudenreichii ssp. shermanii JS, or placebo twice daily. On the 
whole, no significant difference was noted between the SCORAD scores of probiotic 
and placebo groups. But in subgroup analysis of allergen-sensitized infants, L. 
rhamnosus GG supplemented group showed a SCORAD improvement of 26.1 points 
compared to 19.8 points in the placebo group (p=0.036). Similarly, in infants who are 
not treated with antibiotics, treatment effect was noted in only the L. rhamnosus GG 
supplemented group with a mean SCORAD improvement of 38.4 points versus 28.5 
points in the placebo group (p=0.008). Negative effects between the combinations of 
L. rhamnosus GG and other probiotic strains suggested that these strains suppressed 
the benefits of L. rhamnosus GG when used alone. Strain-specific effects and 
interactions between probiotics need further evaluation.  
 
Other strains such as L. fermentum VRI-033 PCC was administered in another 
randomized study to half of the 56 infants enrolled for 8 weeks [142]. These 
probiotic-treated infants with moderate or severe eczema showed significant 
improvement in SCORAD scores (p = 0.03) but not the placebo group. At week 16 





compared with 63% in the placebo group (p = 0.01). Eventually, 54% of the children 
in the probiotic group had mild eczema compared to 30% in the placebo group. 
Probiotic supplementation may accelerate the natural improvement of eczema in 
young children with apparent effects 2 months after cessation of supplementation.  
 
Interestingly, 3 other subsequent studies conducted using L. rhamnosus GG in recent 
years did not yield favourable results. Brouwer et al. [143] supplemented either L. 
rhamnosus or Lactobacillus GG in hydrolysed whey-based formula for 3 months to 
17 infants less than 5 months old with eczema in each group. However, this study did 
not demonstrate any significant effects of probiotics on SCORAD, sensitization, 
inflammatory parameters or cytokine production. Similarly, Foster-Holst et al. [144] 
did not demonstrate L. rhamnosus GG to be an effective treatment for eczema in a 
randomized, double-blind, placebo-controlled study with 54 infants randomized to 
5x109 CFU of L. rhamnosus GG or placebo twice daily for 8 weeks. The most recent 
study conducted in 2007 by Gruber et al. [145] randomized mild-to-moderate atopic 
dermatitis infants aged 3-12 months to 5x109 CFU of L. rhamnosus GG (n=54) or 
placebo (n=48) for 12 weeks and showed no therapeutic effect of probiotic even when 
sub-analysed by age, eczema severity and hydrocortisone treatment.  
 
Furthermore, lack of beneficial effect of probiotics has been observed in older 
adolescents and adults with asthma. In the randomized controlled crossover trial, no 
significant difference in asthma control and inflammation was found between the 
active group supplemented with 450g of yoghurt with 7.6x108 CFU/g of L. 
acidophilus and the placebo group supplemented with yoghurt containing 3.4x108 





Another double-blind, placebo-controlled study was conducted on birch-pollen 
allergic young adults who were supplemented with L. rhamnosus before, during and 
after the pollen season. But the probiotic supplementation did not alleviate the 
respiratory and eye symptoms of the patients nor reduce medication use during and 
after the pollen season [147]. Most recently, 108 CFU/ml of L. casei in 100ml of 
fermented milk was administered to 2 to 5 year old preschool children with 
intermittent to moderate persistent asthma for 1 year and observed longer mean time 
(4.1 months) free of episodes of asthma as compared to placebo (3.3 months). But this 
difference was not statistically significant (p=0.23) [148]. A systemic review of these 
studies concluded that there were no positive effects of probiotic on the treatment of 
asthma [149]. In this review, the effects of probiotics for the treatment of allergic 
rhinitis were also assessed. In 9 of the 12 studies evaluated (4 perennial and 8 
seasonal allergic rhinitis studies), probiotics improved at least one clinical symptom 
severity or the amount of medication used or the number of episodes of allergic 
rhinitis [148, 150-157]. No positive probiotics effect was noted in 3 seasonal allergic 
rhinitis studies but it is of note that the clinical symptoms did not deteriorate in these 
subjects [147, 158]. Probiotic supplementation did not show beneficial effects on the 
total and specific IgE and cytokine and chemokine levels in 9 of these randomized 
controlled trials which immunological measurements were taken. In conclusion, 
probiotics may have beneficial effects in allergic rhinitis by reducing symptom 
severity and medication use.  
 
Due to these conflicting results and difference in study design, meta-analyses and 
reviews of these studies have proposed that although probiotics are likely to play a 





effect is uncertain and cannot be recommended as standard therapy for allergic 
diseases [159-162]. Probiotics may have more beneficial effects when used early in 
life as a primary prevention measure while immune responses are still developing and 







Table 1-4 Summary of clinical trials evaluating the role of probiotic supplementation in the treatment of atopic dermatitis  
Study No. of Subjects   Age 
Range 
(mean) 
















L. rhamnosus GG  5 x 108 
CFU/g  
1 month 26 (17-38) / 
21(14-31) # 
Improvement in SCORAD from 
median 26 to 15 (p=0.008) but not in 
placebo 
Isolauri et al., 
2000[138]   
Probiotic (a) = 9 
Probiotic (b) = 9 
Placebo = 9 
4.6 
months 
(a) L. rhamnosus GG  
(b) B. lactis Bb-12 
1) 3 x 108 
2) 1 x 109 
CFU/g 
2 months 13 (6.5-21.0)/ 
10 (6.5-26.5) # 
Improvement in SCORAD-  
B lactis Bb-12 to 0 (0-3.8),  
LGG group to 1 (0.1-8.7),  
vs control 13.4 (4.5-18.2)  




Probiotic (a) = 14 
Probiotic (b) = 13 




(a)Live  L. rhamnosus GG  
(b)Heat-inactivated 
     L. rhamnosus GG 
1 x 109 
CFU/g 
< 1 week to  
>10 months 
(a) 19 (4-47) 
(b) 15 (0-29) /  
13 (4-29) # 
More improvement with viable LGG 
(p=0.02) than for placebo group but 
diarrhea with heat inactivated LGG 
Rosenfeldt  
et al.,  2003 
[140] 






L. rhamnosus 19070-2  &  
L. reuteri DSM 122460 






then 6 weeks 
treatment/placebo 
40 (18-66) /  
35 (15-66) * 
Improvement in extent of eczema 
from a mean of 18.2% to 13.7% (p 
=0.02) and SCORAD in IgE 
sensitized group decreased 2.4 
(p=0.04) 
Viljanen et al.,  
2005 [141] 
Probiotic (a) = 80 
Probiotic (b) = 76 
Placebo = 74 
1.4 – 11.9 
months 
(a) L. rhamnosus GG 
(b) LGG, L rhamnosus 




(a) 5 x 109  
(b) 5x 109, 
5x 109,  
2 x 108,  
2 x 109 
CFU twice 
daily 
4 weeks 34.3(17.2) /  
33.3 (15.0) /  
29.9 (12.2) † 
Mean SCORAD no difference 
between treatment groups 
immediately or 4 weeks after 
treatment. LGG group showed a 
greater reduction in SCORAD in IgE-
sensitized infants (p=0.036) and 
infants without antibiotic treatment 
(p=0.008) 
# Median (IQR) 
* Median (range) 





Table 1.4  Summary of clinical trials evaluating the role of probiotic supplementation in the treatment of atopic dermatitis (continued) 
 
 
Study No. of Subjects   Age 
Range 
(mean) 






Effect of probiotic on  
outcome measures 
 






L. fermentum VRI-033 
PCC 
1 x 109 
CFU twice 
daily 
8 weeks 40.8 (6.8) /  
44.0 (10.4) †  
Improvement in SCORAD at 16 
weeks (p = 0.03) but not the placebo 
group. 92% probiotic-treated subjects 
had better SCORAD than 63% in 
placebo group (p = 0.01) 
Brouwer et al., 
2006 [143] 
Probiotic (a) = 17 
Probiotic (b) = 16 
Placebo = 17 
1.1 -5.2 
months 
(a) L. rhamnosus  
(b) Lactobacillus GG 
(a) 5 x 109 
(b) 3 x 108 











L. rhamnosus GG 5 x 109 8 weeks 43.3 / 41.4 ¥ No improvement 






L. rhamnosus GG 5 x 109 12 weeks 24.6 (8.8) /  
23.6 (7.8) † 
No improvement 
 
# Median (IQR) 
* Median (range) 










1.4.3 Probiotics for the prevention of allergic disease  
 
Gut microbiota contribute as one of the most abundant sources of microbial antigen 
exposure to stimulate the early immune system. Thus the potential benefits of 
probiotics early in life on a developing immune system may provide a window of 
opportunity for the primary allergy prevention. The first study that addressed the role 
of probiotics in primary prevention by Kalliomaki et al. [8] reported a reduction by 
50% on the incidence of eczema by 2 years of age in the L. rhamnosus GG treated 
group (23%) as compared to the placebo group (46%) (Relative risk RR 0.51; 95% 
confidence interval CI 0.32-0.84). This double-blind, randomized placebo-controlled 
trial recruited 132 evaluable pregnant women with a family history of atopic diseases 
and administered 1 x 1010 CFU L. rhamnosus GG daily for the last 2-4 weeks of 
pregnancy. This dose of probiotic was continued postnatally to the breastfeeding 
mothers or the infants who were on total formula fed directly in water for 6 months. 
This reduction in eczema persisted at the 4 and 7 year follow-up, where there was a 
43% reduction in the risk of developing eczema (RR 0.57; 95% CI 0.33-0.97) at 4 
years of age [163]. The cumulative risk of developing eczema during the first 7 years 
of life was 42.6% in the probiotic-treated group, compared with 66.1% in the placebo 
group (RR 0.64; 95% CI 0.45–0.92) [164]. However, no differences were observed 
for total or specific IgE concentration and skin-prick-test reactivity. Although at 4 
years of age, there was a reduction in exhaled nitric oxide production in the probiotic-
treated group compared to healthy age-matched individuals (from 14.5 to 10.8 parts 
per billion), effect on respiratory allergic diseases, namely asthma and allergic rhinitis, 






In a second preventive study in another Finnish population by Kukkonen et al., a 
mixture of 4 probiotic strains, namely L. rhamnosus GG, L rhamnosus LC705, B. 
breve Bb99 and Propionibacterium freudenreichii ssp. shermanii JS was administered 
with prebiotic galacto-oligosaccharides to 925 randomized infants both prenatally to 
mothers and postnatally for 6 months [165].  This combined supplementation of 
probiotics and prebiotics reduced eczema (Odds Ratio OR, 0.74; 95% CI, 0.55-0.98;  
p = 0.035) and atopic eczema (OR, 0.66; 95% CI, 0.46-0.95; p = 0.025) but no effects 
on sensitization or other allergic diseases at 2 years of age. Kukkonen and colleagues 
continued to follow up this large study cohort up to 5 years of age [166]. This recent 
publication revealed that although probiotics did not confer protection against eczema 
(39.3% vs. 43.3% in placebo), atopic eczema (24.0% vs. 25.1% in placebo), allergic 
rhinitis (20.7% vs. 19.1% in placebo), or asthma (13.0% vs. 14.1% in placebo) at 5 
years of age, subset analysis showed decreased IgE-associated allergic diseases in 
probiotics-treated caesarean-delivered children (24.3% vs. 40.5% in placebo; OR 0.47, 
95% CI 0.23-0.96, p = 0.035).  
 
These initial studies provided positive results but were not substantiated by 
subsequent studies in other populations. Another double-blind, placebo-controlled 
trial conducted in an Australian population recruited 178 pregnant mothers with an 
allergic disease to supplement 3 x 108 CFU of L. acidophilus to their babies directly 
after birth for 6 months [167]. At the end of the supplementation period, atopic 
dermatitis rates were similar in the probiotic (25.8%) and placebo (22.7%) groups (p= 
0.629). At 12 months of age, no difference was noted with 43.2% of eczematous 
toddlers in the probiotic group and 39.1% in the placebo group. Interestingly, the rate 





with a significantly higher proportion of these children with atopic dermatitis and 
sensitization (p = 0.04). There was no difference in the rate of food allergic subjects 
between the groups but children who received probiotic had significantly higher rate 
of wheezing (OR 2.45; 95% CI 1.11-5.39; p=0.024) in the second 6 months of life. 
Subsequent follow-up to 2.5 years also did not show a reduction in the risk of eczema 
with 42% in the probiotic (n=31/74) compared to 34% in the placebo group (n=25/76). 
No significant reduction in any other allergic disease or allergen sensitization was 
observed [168].  
  
In a Swedish study, Abrahamsson et al. [169] also could not demonstrate a protective 
effect of 1x 108 CFU of L. reuteri on infant eczema when administered daily from 
gestational week 36 until 12 months of age. However, the probiotic-treated infants 
had less IgE-associated eczema (8% versus 20% in placebo group, p = 0.02) and less 
sensitization in a subgroup with allergic mothers (14% versus 31% in placebo group, 
p= 0.02) at 2 years follow-up.  
 
Several meta-analyses and reviews were performed for these studies conducted before 
2008. The Cochrane review by Osborn et al. concluded that there was then 
insufficient evidence to recommend the use of probiotics in prevention of allergic 
disease due to the inconsistencies between study designs and probiotic strain [170]. 
Betsi et al. however recommended that L. rhamnosus GG seems to be effective for 
primary prevention of eczema but more randomized controlled trials needs to be 
conducted for a more conclusive inference [159]. The meta-analysis by Lee et al. [160] 
included the data of three follow-up studies from the same study population of 





probiotics on paediatric atopic dermatitis might be inappropriate and should be 
considered with care. 
Subsequent randomized double-blind, placebo-controlled trials were published 
recently. Kopp et al. [171] adopted a similar study design to that of the Kalliomaki et 
al. study with the hope to elucidate comparable positive results in the German 
population. The same probiotic strain, L. rhamnosus GG was administered at 5 x 109 
CFU twice daily to 50 evaluable infants 4 to 6 weeks prenatally and then postnatally 
for 6 months. This dose was higher than the 1 x 1010 CFU daily of L. rhamnosus GG 
that was administered in the Kalliomaki et al. study. However, no preventive effect of 
probiotic on the development of eczema was observed in this German population. The 
cumulative incidence of atopic dermatitis was 38% in the probiotic group and 31.8% 
in the placebo group (p=0.53). No differences in the total IgE concentration or 
sensitization to inhalant allergens were noted. Moreover, children with recurrent (≥5 
episodes) wheezing bronchitis during the first 2 years were more frequent in the 
probiotic group (26%) as compared with 9.1% in the placebo group (p=0.03). 
Eventually, Kopp et al. published a review [172] which argued that although the 
concept of using probiotics for primary prevention of allergy seems beneficial, further 
studies need to evaluate specific probiotic strain, the timing, dose and method of 
administration to determine whether there will be a favourable effect on subgroups.  
 
Differential effects of two probiotic species were further examined by the most recent 
primary prevention study by Wikens et al. [173] using L. rhamnosus HN001 and B. 
animalis subsp lactis strain HN019 in another double-blind, randomized placebo-
controlled trial conducted in New Zealand. Pregnant women with atopic history (or 





probiotic group or the placebo group to be supplemented with the capsules at 35 
weeks gestation. Following which, the breastfeeding mothers were continued to be 
supplement till 6 months postpartum or the bottle-fed infants were started on the 
capsules till 2 years of age. This is the longest supplementation period in the primary 
prevention studies ever conducted. Only the infants who received L. rhamnosus but 
not the B. animalis subsp lactis had a significantly reduced risk of eczema (14.8%) 
compared with placebo (26.8%) (p=0.01) by 2 years evaluation. The risk of 
developing SCORAD ≥10 was also reduced in the L. rhamnosus group only (24.0% 
vs. 38.7% in placebo, p=0.009).  There was no significant difference of L. rhamnosus 
(21.3%) or B. animalis subsp lactis (23.5%) on sensitization to any allergens 
compared to placebo (28.8%) (p=0.42). Other allergic diseases were not evaluated. 
This suggests a protective effect for only L. rhamnosus HN001 but not B. animalis 
subsp. lactis strain HN019 and therefore different probiotic species and strains can 
exert diverse effects on allergic disease.  
 
Despite the disparities between results of different studies, the protective potential for 
probiotics in the pathogensis of eczema is evident. Responses may be affected by 
strain-specificity of probiotic effects as closely related strains can show significant 
different adhesion, competitive exclusion and pathogen displacement properties [174]. 
In the Taylor et al. study [167], L. acidophilus was previously undefined and did not 
demonstrate a positive reduction of eczema. Probiotics combination needs to be 
evaluated to ensure that desirable properties are enhanced and not counteracted. 
Furthermore, the pattern of early allergen exposure including the variations in the 
timing, dose, interval and regularity may provide the key about how probiotics exert 





German population [171]. Despite using the same concept of the Finnish study 
published by Kalliomaki et al. [8] that showed a preventive effect of L. rhamnosus 
GG on eczema, the Kopp et al. study failed to demonstrate beneficial effects of 
probiotics. Host susceptibility to microbial influence and to colonization could be 
different in various populations. Functional genetic polymorphisms in related 











Table 1-5 Summary of clinical trials evaluating the role of probiotic supplementation in the primary prevention of atopic diseases 
 
 
Study No. of 
Subjects 
Probiotic Dose Supplementation Age of 
evaluation 
(years) 
Effect of Probiotics on Clinical Endpoints 
Prenatal Postnatal Eczema Sensitization Food Allergy 
Kalliomäki et al. , 
Finland 2001 [8] 
n=132 Lactobacillus rhamnosus 
GG (LGG) 
1 x 1010 
CFU daily  
Yes 6 months 2 Reduced No effect Not evaluated 
Kukkonen et al., 
Finland, 2007 [165] 
n=925 Mixture of 4 strains with 
prebiotic galacto-
oligosaccharides 
1. LGG and  
2. L rhamnosus LC705 











Both 2 x 109 
CFU twice 
daily  
Yes 6 months 2 Reduced No effect No effect 
Taylor et al., 
Australia, 2007 
[167] 
n=178 L. acidophilus 3 x 108 CFU 
daily 
No 6 months 1 No effect Increased rate of 
sensitization 
No effect 
Abrahamsson et al., 
Sweden, 2007 [169] 
n=188 L. reuteri 1x 108 CFU 
daily 
 














Table 1.5  Summary of clinical trials evaluating the role of probiotic supplementation in the primary prevention of atopic diseases (continued) 
 
 
Study No. of 
Subjects 
Probiotic Dose Supplementation Age of 
evaluation 
(years) 
Effect of Probiotics on Clinical Endpoints 
Prenatal Postnatal Eczema Sensitization Food Allergy 
Kopp et al., 
Germany, 2008 
[171] 
n=94 LGG 5 x 109 CFU 
twice daily  
 
Yes 6 months 2 No effect No effect Not evaluated 
Wickens et al., New 
Zealand, 2008 
[173] 
n=474 (a) L. rhamnosus HN001 
(b) B.animalis subsp 
lactis strain HN019 
(a) 6 x 109  
(b) 9 x 109 
CFU daily  
 
 









1.4.4 Impact of probiotics on acute infectious illnesses  
 
Probiotics may reduce the incidence of infections by stimulating humoral and cellular 
immunity. This immunostimulatory effect of probiotics had previously been shown to 
improved resistance to respiratory infections in infants attending day care in which L. 
rhamnosus GG supplemented children had fewer days of absence from day care 
because of illness (age adjusted 5.1 (4.6 to 5.6) vs. 5.7 (5.2 to 6.3) days, p=0.09) 
suggesting that probiotics may lessen the severity of respiratory infections. There was 
also a relative reduction of 17% in the number of children who suffered from 
respiratory infections (otitis media, sinusitis, bronchitis, and pneumonia) (age adjusted 
OR 0.75, 95% CI 0.52-1.09; p=0.13) and a 19% relative reduction in prescribed 
antibiotics for respiratory infections (adjusted OR 0.72, 95% CI 0.50-1.03; p=0.08) in 
the probiotic group [175]. Even though the age adjustment reduced the differences 
between the groups, the results were near to significance and consistently support the 
beneficial effects of L. rhamnosus GG. However, in another Israeli multicenter trial, B. 
lactis BB12 and L. reuteri were not found to protect against respiratory infections 
among children in day care. Nonetheless, the use of L. reuteri but not B. lactis BB12 
was associated with significantly fewer days of fever, lesser visits to the clinic, lesser 
absences from the child care and fewer prescribed antibiotics in this study [176].  
 
Data collected from probiotic clinical trials in the primary prevention of eczema also 
evaluated its effects on infections. In the study by Taylor et al., infants who received L. 
acidophilus postnatally for 6 months did not reduce the risk of atopic dermatitis or 
respiratory infections and were in fact more likely to be prescribed antibiotics (27.0%) 
compared to the placebo group (17.0%) [167]. Apart from this study, other studies 





who received probiotic-supplemented formula such as that of B. lactis and S. 
thermophilus [177]. Fewer antibiotic courses throughout the intervention of a mixture 
of 4 probiotic species by Kukkonen et al. [178] was also observed. Infants received 
lesser antibiotics in the synbiotic group (23%) than in the placebo group (28%) (OR 
0.74, 95% CI 0.55–1.00; p=0.049). During the follow-up period to 2 years of age, 
respiratory infections occurred less frequently in the synbiotic group (93%) than in the 
placebo group (97%) (OR 0.49, 95% CI 0.27–0.92; p=0.023).  
 
In this Kukkonen et al. study [178], the synbiotics supplementation failed to prevent 
episodes of gastroenteritis which was equally common in the synbiotic (74%) and 
placebo groups (71%) (p=0.736). In the Finnish study among children in day care, L. 
rhamnosus GG supplemented in milk also did not reduce incidence of gastroenteritis 
(2.9 (2.7 to 3.2) vs. 3.0 (2.7 to 3.3) days in placebo, p= 0.74) [175]. Similarly, the 
Australian study by Taylor et al. [167] did not observed reduction in gastrointestinal 
infections in the L. acidophilus supplemented group as well. Conversely, in the 
Rosenfeldt et al. study discussed earlier with regards to the effect of  L. rhamnosus 
19070-2 and L. reuteri DSM 122460 in the treatment of children with eczema [140], it 
was found that probiotics reduced gastrointestinal symptoms (39% during the placebo 
period vs. 10% during active treatment, p=0.002) and improved small intestinal 
permeability measured by the lactulose-mannitol test in this cross-over study [179]. 
Furthermore, stabilization of the intestinal barrier function was positively associated 








1.5 Safety and adverse effects of probiotics 
 
Probiotics have been regarded as Generally Recognized as Safe (GRAS) by the Food 
and Agriculture Organization (FAO)/World Health Organization (WHO) expert panel 
guidelines for probiotic [56, 180]. However, probiotics are strain-specific and based 
on the U.S. Federal Food, Drug, and Cosmetic Act. [181], probiotics may be regulated 
as dietary supplements, foods, or drugs depending on the product’s intended use. The 
report of the Joint FAO/WHO Working Group on Drafting Guidelines for the 
Evaluation of Probiotics in Food recommended that it is necessary to know the genus 
and species of the probiotic strain to evaluate the functionality and safety.  
 
Although there had been only 1 case of significant gastrointestinal effects associated 
with heat-inactivated L. rhamnosus GG [139] in the probiotics treatment and 
prevention studies evaluated above, there are potential adverse effects due to 
transmigration on localized and generalized immunologic [182], metabolic and 
physiologic systems [183]. Antibiotic-resistance transfer within the gastrointestinal 
tract between probiotics and pathogenic bacteria is also an area of concern [184]. But 
a few cases reported probiotic bacteremia or fungemia have occurred in 
immunocompromised patients or patients with underlying chronic disease. There had 
been 2 reports of Lactobacillus bacteremia related to probiotic use in premature 
infants with short gut syndrome who were fed via gastrostomy or jejunostomy after 
consumption of L. rhamnosus GG supplements [185, 186]. Another case of L. 
rhamnosus GG endocarditis was reported in a 4 month old infant who consumed 1010 
CFU of L. rhamnosus GG daily for antibiotic-related diarrhoea after cardiac surgery 





use in healthy persons even though the recent widespread use of probiotics especially 
supplementation in infant formula may increase the prevalence of such problems. 
 [188]. 
Probiotics may contribute to the host’s energy metabolism and enhance the uptake of 
nutrients to increase nutritional status and improve physical growth. Normal healthy 
infants who received L. rhamnosus GG-supplemented formula for 6 months in a 
double-blind, randomized study grew to a significantly higher length and weight than 
the infants who received regular formula [189]. Other studies however observed 
similar normal growth in both probiotic-treated and placebo study groups and did not 
find improved growth with probiotics. In a study in the United States, growth was 
similarly adequate in 3-24 month old infants who received a standard milk-based 
formula containing B. lactis and Streptococcus thermophilus or unsupplemented 
formula.[177]. Another study in France concluded that infants fed a mixture of 
probiotics or synbiotics showed similar weight gain compared with those fed a control 
formula [190]. A recent study on extensively and partially hydrolyzed formulas 
supplemented with L. rhamnosus GG also supported normal growth in infants and 
indicated that probiotic is well tolerated and safe [191]. The study from Kukkonen et 
al. which evaluated the role of probiotic supplementation in the primary prevention of 
atopic diseases [165] also found that the anthropometric measures at the ages of 6 
months and 2 years showed similar normal growth in the probioic-treated and placebo 









1.6 Gaps in the literature and Aims of the study 
 
Probiotic supplementation in early life is considered an attractive strategy for the 
primary prevention of allergic diseases. The eventual test of such a strategy lies in 
intervention studies in the form of clinical trials. Probiotics have the potential to be 
the ideal interventional strategy as they are safe, can be administered from birth, and 
can be conveniently added to milk. There were other published trials in the Western 
countries where the effect of probiotics on allergic diseases were studied. There is a 
critical need for further contribution of data to support or refute the current body of 
evidence on the prophylactic effect of probiotics in primary allergy prevention in 
large studies of other populations. Our study intended to fill this vacuum as well as 
add new information on the potential effects by examining the effect of probiotics on 
atopy and immunological responses in an Asian population through a large 
randomized clinical trial with a combination of two probiotic strains pre-mixed into 
the formula, as opposed to taking it separately. If proven beneficial, probiotics can be 
easily added to milk. This would be a major step in reducing the significant morbidity 
associated with atopic disease and translate into ideas for novel strategies in the 
primary prevention of allergic diseases in children. Additionally, the prospective 
nature of this study would enable evaluation of the natural history of individuals at 
high risk of atopic disease in Singapore. The prospective design of our study excluded 
recall bias and was the best way to study disease associations as information on 
exposures and confounders were measured in time. To our knowledge, this was the 
largest prospective study on Singaporean children at high-risk for atopy. It would thus 






1. This first aim of the study was to assess the effect of administration of  
probiotics (Bifidobacterium longum and Lactobacillus rhamnosus) 
supplemented cow’s milk based infant formula from the first day of life for 6 
months on the prevention of allergic diseases, namely eczema, asthma, allergic 
rhinitis, and allergic sensitization in the first 2 years of life in Asian infants at 
risk of allergic disease. In addition, we correlated atopic outcome at 2 years of 
age with immune responses at birth and 1 year of age. The incidence of 
allergic diseases in a high risk cohort (placebo group) and the impact of 
covariates such as early life infections, family size, presence of pets and 
passive smoking and other environmental factors were ascertained. 
 
Apart from allergies, prevention of childhood infections has long been recognised as 
an important target of global health. Infectious disease is the number one cause of 
mortality in children all over the world. Probiotics are safe and easily available. There 
is evidence that probiotics can modulate local and systemic immune responses, 
resulting in decrease in infectious disease, especially diarrhoeal disease [106-120], 
and increase efficacy to vaccination [86-91, 93-97]. Data is lacking in longitudinal 
studies with regards to prophylactic use of probiotics on other infections in children, 
of which viral infections predominate. There is also little information regarding the 
effect of probiotics on parenterally-administered vaccines especially for important 
infections in the region, such as Hepatitis B. Viral hepatitis is a common cause of 
liver disease in Asia. Hepatitis B is the most common form and the Ministry of Health, 
Singapore reported a prevalence of 4.1% in 1999 and 2.7% in 2005 amongst residents 
aged 18-69 years. Hepatitis B continues to constitute a major public health concern 





national childhood immunisation programme has since been implemented in 1987 for 
all newborns and we hypothesize that probiotics may have an adjuvant effect resulting 
in increased immunogenicity with the vaccination, especially in atopic subjects. 
Delayed immune maturation in atopic infants has been proposed with a deficiency in 
the ability of T cells to produce Th1-like cytokines on stimulation [192] and exhibit 
reduced antibody responses to vaccination [193]. An increase in systemic immune 
response to vaccination would suggest that probiotics may be good vaccine adjuvants 
and could be exploited in future research, particularly for vaccine development of 
important infections in Singapore. Increasing the protective antibody response is an 
attractive strategy to provide long term protection against infection. We proposed that 
the efficacy of parenteral vaccines can possibly be improved with concomitant or 
prior use of the probiotics. 
 
2. The second aim of the study was to assess the effect of probiotic 
supplementation in the first 6 months of life on specific antibody response 
against Hepatitis B at 1 year of life as a surrogate marker for infant immune 
response to vaccination.  
 
3. The third aim of the study was to assess the effect of early regular 
supplementation of probiotics in the infant diet on protective benefit against 
diarrhoeal and febrile illnesses. The effect on the use of antibiotics and 
incidence of hospitalization was assessed. We further seek to determine if this 
effect was short term (6 months, during supplementation) or longer-lasting (2 






As probiotics consumption are generally considered as safe and no current reports 
have described serious adverse effects related to probiotic use in healthy persons 
[188], probiotics are increasingly being used in infancy with more and more products 
available on the market with high dose of combinations of viable probiotics. 
Furthermore, probiotics are generally regulated as health supplements and not drugs. 
Thus the long term use of live probiotics in newborn babies should be continually 
evaluated with respect to different probiotic strains and combinations. Probiotic may 
also contribute to the host’s energy metabolism and enhance the uptake of nutrients to 
increase nutritional status and improve physical growth.  
 
4. The fourth aim of the study was to document safety and impact on growth of 

















2 Chapter 2: Materials and Methods 
 
2.1 Study Design 
 
A double-blind, placebo-controlled randomized study (ClinicalTrials.gov Identifier: 
NCT00318695) was conducted to assess the effect of probiotic supplementation in the 
first 6 months of life on the incidence of allergic diseases and effects on safety aspects 
in Asian infants at risk of allergic disease with a two year follow-up. We recruited 253 
families with a history of allergic disease from the antenatal clinics at the National 
University Hospital, Singapore, between May 2004 to June 2006. Parents were 
approached and informed of the purpose and design of the trial. The benefits of 
breastfeeding were emphasized and only those who did not want to totally breastfeed 
their children were candidates for inclusion in the study. 
2.2 Eligibility 
2.2.1  Inclusion criteria 
2.2.1.1  Pre-delivery evaluation 
 
• Either parent or sibling (first-degree relative) with a history of physician-
diagnosed asthma, allergic rhinitis or eczema and a positive skin prick test to 
the dust mites, Dermatophagoides pteronyssinus and/or Blomia tropicalis, 
which are the most common cause of inhalant allergen sensitization in our 
atopic population [194] 
• Parents agreed to the subject’s participation in the study as indicated by 
parent’s signature on the informed consent form (refer to Appendix A). 
• The parents were willing to comply with procedures and were able to keep to 





2.2.1.2  Post-delivery evaluation  
(refer to Screening Form, Appendix B) 
 
• The subject was born at more than 35 weeks gestation and weighed more than 
2 kilograms.  
• The subject did not have major congenital malformations or major illness as 
judged by the doctor. 
• The subject was in otherwise good, stable health on the basis of medical 
history, physical examination, and the family appeared to be able to 
successfully complete this trial on the basis of an interview. 
2.2.2  Exclusion criteria 
 
• The subject was excluded when the parent was assessed to be mentally or 
legally incapable of informed consent.  
• The parents were unable or unwilling to comply with procedures. 
• Parents who chose to breast-feed exclusively were not considered for the study.   
2.3 Randomisation 
 
Computerized randomization was carried out in blocks of 6 (each group having 3 
codes) based on a 1:1 allocation, with the lowest number allocated sequentially as per 
prepared by the milk sponsor, Nestle Research Centre Switzerland. The identical tins 
of milk formula were labelled with unique trial numbers following the order of the 
randomisation list by an independent team to ensure concealment of allocation. Six 
sealed envelopes containing the identity of the milk formula were maintained by the 
Singapore Clinical Research Institute (previously known as Clinical Trial and 
Epidemiology Research Unit), Singapore. Investigators, study team and all subjects 





2.4 Probiotic Supplement and Infant Formula 
 
Subjects received at least 60ml (9.26 g) a day of commercially available cow’s milk 
based infant formula (Nestle Nan 1®), with either probiotic supplementation 
(Bifidobacterium longum BL999 (ATCC: BAA-999 designation BB536, Morinaga, 
Japan) 1×107 CFU/g and Lactobacillus rhamnosus LPR [CGMCC 1.3724] 2×107 
CFU/g) or without, initiated within 12 hours for the first 6 months of life.  The infants 
in the probiotic group, therefore, received at least 2.8x108 CFU of probiotic bacteria 
per day. Mothers were then free to decide whether to make up the remainder of the 
baby feeds with either the trial formula, or to supplement with breast milk, or another 
infant formula. Both B. longum and L. rhamnosus conform to the Food and 
Agriculture Organization (FAO)/World Health Organization expert panel guidelines 
for probiotic [180].  
 
Compliance was monitored by completion of a daily diary chart (Appendix C) by 
parents and biweekly phone contacts (Appendix D) with the study nurses for the first 
6 months. Non-compliance was defined as consumption of less than 60 ml of trial 
milk formula daily for a duration of 3 days during the intervention period (birth to 6 
months of age).  
 
The milk formula with probiotics was not available commercially and was specially 
manufactured by Nestle®, Vevey, Switzerland for this study.  Both probiotic 
supplemented and control formula were not hydrolyzed and not supplemented with 
prebiotics. The formula feeds (test and control) tasted and appeared identical. Quality 
control testing by the manufacturer showed that the probiotic bacteria in the 





Weaning to solids was allowed at between 4 to 6 months of age according to local 
practices, but parents were advised to avoid potentially allergenic foods including 
eggs, shellfish and peanuts until after the first birthday (refer to Weaning Practices 
Form, Appendix B). 
 
2.5 Ethical Considerations 
 
Written informed consent was obtained from all families pre-delivery. The parent’s 
written informed consent to participate in the trial was obtained after a full 
explanation had been given of the treatment options, including the conventional and 
generally accepted methods of treatment and the manner of treatment allocation. After 
the delivery, subject was evaluated for remaining eligibility criteria and randomized if 
all were met. The right of the parents to refuse the infant’s participation without 
giving reasons was respected. Similarly, the parents remained free to withdraw at any 
time from protocol treatment without giving reasons and without prejudicing the 
subject’s further treatment. The study was approved by the National University 
Hospital’s ethics review committee (DSRB Ref Code: B/00/322). This trial was 
conducted in accordance to the principles of Good Clinical Practice (GCP) and 
complied with the requirements of the Singapore Guidelines for GCP. The 
administration of probiotics in standard infant cow’s milk formula is discussed in 









3 Chapter 3: Effects of Probiotic Supplementation on 





Probiotic bacteria promote immunoregulatory functions and present as a promising 
strategy in primary prevention of allergy.  Probiotic supplementation has been 
examined in several double-blind, placebo-controlled randomized clinical trials [8, 
163-167, 169, 171, 173] to examine the effect of probiotic supplementation in primary 
allergy prevention on clinical subjects. However, despite the rigorous testing of this 
concept on clinical subjects, 4 recent meta-analyses of the published clinical trials 
have concluded that the role of probiotics in allergy prevention either remains 
inconclusive due to varied study designs and results [170], or has some protective 
effect on eczema alone [160]. No beneficial effects on allergen sensitisation and 
respiratory allergies has been observed in the studies conducted, except for 
Abrahamsson et  al. study [169] which showed an effect of reduced sensitisation in 
infants with atopic mothers. Other recent studies noted negative effects on allergen 
sensitisation and wheezing [167, 171]. Generally, the meta-analyses concluded that 
the concept of using probiotics for primary prevention of allergy is likely, but further 
studies are needed to evaluate specific probiotic strains, the timing, dose and method 
of administration to determine the plausible beneficial effects [159, 172].  
 
This study assessed the effect of administration of probiotic (Bifidobacterium longum 





the first day of life for 6 months on the prevention of allergic diseases and 
sensitization in the first 2 years of life in Asian infants at risk of allergic disease.  
 
3.2 Materials and Methods 
3.2.1 Clinical Assessment 
 
The primary clinical outcome measure was the incidence of eczema, and the 
secondary outcome measures were asthma, allergic rhinitis and allergen sensitization. 
Infants were evaluated by a paediatrician at 1, 3, 6, 12 and 24 months of age, which 
involved a detailed history, recording of anthropometric data and clinical examination, 
including looking for the presence of allergic diseases. Questionnaires (not validated) 
were also administered by the candidate and research nurses at these visits to record 
clinical disease and environmental exposures, including day care, sibship, use of 
antibiotics, smoking and pets (refer to Follow-up Form, Appendix B). Biweekly 
phone calls were performed for the first 6 months after which monthly phone contacts 
were done to collect data on the health status of the children (Appendix D). 
 
Eczema was defined as a pruritic rash over the face and/or extensors with a chronic 
relapsing course, as described by Hanifin and Rajka and modified by Seymour et al. 
for infants [16]. The SCORAD (SCORing Atopic Dermatitis) index was used to 
objectively score the severity of atopic dermatitis [136], which were carried out by the 
paediatricians. Briefly, the doctors applied SCORAD to compare the patient’s lesions 
to standard colour slides and graded each of the six objective intensity items, namely 
erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, 
on a scale from 0-3. The two subjective intensity items, pruritus and insomnia, were 





The extent of the disease was determined by grading skin involvement on different 
parts of the body. The results from the three parameters were then introduced into a 
weighted mathematical formula to calculate the final results (Refer to Appendix E). 
 
Asthma will be diagnosed if the child had three episodes of nocturnal cough with 
sleep disturbances or wheezing, separated by at least seven days, in a setting where 
asthma was likely and conditions other than allergy have been excluded [17]. The 
subject will be diagnosed with allergic rhinitis if the child had rhinorrhea, nasal 
obstruction, nasal itching and sneezing which were reversible spontaneously or with 
treatment that was not due to a respiratory infection as per recommendations from the 
World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma 
workshop (ARIA) [19]. 
 
3.2.2 Determination of serum total immunoglobulin E and skin prick 
tests 
 
Serum samples were collected from cord blood and about 5 ml of blood was drawn 
(to obtain 2.5 ml of plasma) using EMLA® as an anaesthetic at Month 12.  The 
serum/plasma samples were stored at -70°C till assayed. Measurement of total IgE 
was performed by the candidate using the fluoroenzymeimmunoassay method 
(UniCAP® Phadiatop, Pharmacia Diagnostics, Uppsala, Sweden), with a detection 
limit of 0.35kU/L. Pharmacia Diagnostics indicated that this method is precise and 
accurate with intra-assay precision (coefficients of variation between 1.4% and 3.3%) 






Skin prick test was performed by the trained candidate and research nurses at 12 and 
24 months of age using standardized technique with common allergen extracts, 
including soy (Alyostal, Stallergenes Laboratoires, France), milk, egg yolk, egg white, 
dust mite allergens - Dermatophagoides pteronyssinus (Greer Laboratories, Lenoir, 
NC) and  Blomia tropicalis (manufactured in-house [195]). Peanut and shrimp 
allergens (Greer Laboratories, Lenoir, NC) were added to the panel at 24 months old 
skin prick test. Histamine dihydrochloride solution (10mg/ml) was used as a positive 
control and solvent (50% Cocas 50% Gly) as a negative control. A wheal greater than 
3mm in diameter above the negative control was considered positive [196]. The study 

























3.2.3 Sample size calculation 
 
In this study, the null hypothesis, H0, represented no difference between the probiotic 
and placebo group while the alternative hypothesis, H1, specified a beneficial effect of 
probiotic supplementation in primary allergy prevention as compared to control.  In 
this hypothesis test, a type I error can occur if the null hypothesis was rejected while it 
was in fact true and therefore the probability of the type I error was set at a 
significance level of 0.05. The null hypothesis was to be rejected with the difference 
happening due to 5% chance. A type II error can occur when the null hypothesis H0, 
was not rejected when it was actually false. This type II error was controlled by the 
power of the study (1 - probability of a type II error). The sample size of this study 
depended on the size of the difference to be detected between the 2 groups, the power 
and the level of significance. A two-sided test was carried out rather than a one-sided 
test which assumed that probiotic intervention will performed clinically better than 
the control [197-199].  
 
In conclusion, the sample size was calculated based on the study of Kalliomaki et al. 
in 2001 [8], which reported a reduction in the incidence of eczema from 46% (31/68) 
in the placebo arm to 23% in the probiotic (15/64) group at 2 years of age. We 
therefore anticipated that the incidence of eczema to be approximately 40%, and that 
to detect a relative reduction of 50%, with a power of 90% and two-sided test size of 
5%, 110 subjects were required in each group [200]. This sample size was sufficient 







3.2.4   Statistical Analysis 
 
All statistical analysis was carried out on an intention-to-treat last observation carried 
forward (ITT-LOCF) basis. Intention to treat strategy included all randomized 
subjects in the groups according to original treatment assignment, regardless of 
whether they satisfied the entry criteria, non-adherence with the treatment allocated, 
and subsequent withdrawal or deviation from the protocol. Noncompliant subjects 
were included in the ITT analysis, as in clinical practice, some patients are not fully 
compliant [201-203]. Last observation carried forward approach used the last 
observation prior to drop-out to impute the outcome values and thus reduced the 
effects of lost to follow up subjects [204, 205].  
 
The trial data were collected on printed forms (Appendix B), and subsequently 
entered into CLINTRIAL [197], a specialized software for managing longitudinal trial 
data. This program facilitates interactive entry and data correction, and maintains 
consistent and accurate trial data [206].  Atopy was defined as present when the 
subject had a positive skin prick test, indicating allergen sensitization. Comparison of 
the incidence rates of allergic diseases and atopy in the two treatment groups was 
made using Pearson Chi-square test or Fisher’s Exact test to test for independence and 
determine if there were statistically significant relationships between the categorical 
variables [207]. It tested the null hypothesis that the frequency distribution of the 
incidence rates of allergic diseases and atopy observed in this sample of subjects was 
consistent with the expected as according to the chi-square distribution. The Fisher’s 
Exact test was calculated in the case of a 2×2 contingency table with at least one 
expected cell count less than 5. Using the Fisher’s Exact test, the significance of the 





approximation to the chi-square distribution that assumed a sufficiently large sample 
size [208, 209].  
 
Logistic regression was performed to determine the odds ratio (OR), the associated 
95% confidence interval (CI) and adjust for relevant covariates of the categorical 
dichotomous outcomes of allergic diseases and atopy (occurrence or non-occurrence 
of outcome event) [210]. Binary logistic regression is a generalized linear model 
which is used when the dependents (i.e. allergic disease/atopy) are dichotomous and 
the independents (i.e. covariates) are continuous or categorical variables. The 
prediction of the probability of occurrence of an event is performed by fitting data to a 
logistic curve. The odds ratio is defined as the probability of the outcome event 
occurring divided by the probability of the event not occurring. The 95% confidence 
interval for the odds ratio is obtained as 1.96 standard errors on either side of the 
estimate. The change in value of the independent variable is not associated in change 
in the odds of the dependent variable if the 95% confidence interval around the odds 
ratio includes the value of 1.0 [211, 212].  
 
Due to the non-normality of the data, Mann Whitney U test was performed to assess 
the differences between groups. Mann Whitney U test is the nonparametric equivalent 
of Student’s T test and therefore compares medians instead of means. Normal 
distribution of data is not necessary for use of the Mann Whitney U test [213]. All 
statistical analyses were performed by using SAS v.9.1 and SPSS software (version 
15.0 for Windows). Reporting of this trial was done in accordance to the CONSORT 
(Consolidated Standards of Reporting Trials) statement [214]. The CONSORT 





reporting randomised clinical trials by providing guidance through checklist and flow 




3.3.1 Baseline characteristics and participants 
 
At the antenatal clinic, 3703 families were assessed and out of the 865 eligible 
families, 253 families consented and were recruited into the study. Three subjects in 
the probiotic group and 5 subjects in the placebo group withdrew from the study 
before any follow-up was conducted and were therefore excluded from the analysis. 
At the 24 month visit, there were 124 families in the probiotic arm and 121 families in 
the placebo arm (Figure 3.2). Twin pregnancies were included in the study. The 
ethnicity, gestational age, mode of delivery, birth weight, family atopic history and 
other baseline characteristics of the 2 groups were comparable (Table 3.1 and Table 
3.2). The median gestational age of all subjects was 39.0 weeks (range: 34.0 to 41.9 
weeks). Fifty three percent of them were males and there was a slight imbalance 
between the groups with more males in the placebo group. The overall racial 
composition was 44% Chinese, 46% Malays, 10% Indians and 1% Others. There were 
slightly more first child with 47% in the probiotic group compared to 33% in the 
placebo group. Imbalances seen with gender and birth order between the 2 groups 
were included as potential confounding factors in subsequent analyses with 





































Families assessed for eligibility (n=3703) 
Randomized (n=253) 
(May 2004 – June 2006) 
Ineligible (n=2838) 
Dropout (n=9) 
 Lost to follow-up (n=4) 
  Discontinued intervention  
(n=5) 
- Due to eczema (n=1) 
- Unrelated to study 
formula (n=4) 
 Analyzed at  
1 and 2 years on 
ITT basis 
(n = 121)  
 Analyzed at  
1 and 2 years on 
ITT basis 
(n = 124)  
Dropout (n=5) 
 Congenital birth defect (n=1) 
 Lost to follow-up (n=3) 
 Discontinued intervention 
due to reasons unrelated to 
study formula (n=1) 
Eligible families (n=865) 
                           Start of Follow-up Visits  
Placebo group  
(n=126)  
Withdrew prior to follow up (n=5) 
 Congenital birth defect 
(n=1) 
 Unrelated to study formula 
(n=4) 
Probiotic group  
(n=127)  
Withdrew prior to follow up (n=3) 









Table 3-1 Characteristics of the Study Population 
 
 Placebo (n = 126) Probiotic (n =127) 
   
Gestational age in weeks, Mean (SD)  39.0 (1.1) 38.9 (1.4) 
   
Gender (%)   
   Male 73 (58) 61 (48) 
   
Ethnicity (%)   
   Chinese 53 (42) 57 (45) 
   Malay 55 (44) 60 (47) 
   Indian 15 (12) 10 (8) 
Others 3 (2) 0 (0) 
   
Mode of delivery (%)   
   Lower segment caesarean section 33 (26) 35 (28) 
   Vaginal delivery 93 (74) 92 (72) 
   
Birth Weight (kg)   
   Mean (SD) 3.1 (0.4) 3.2 (0.5) 
   
Length at Birth (cm)   
   Mean (SD) 49.8 (2.8) 49.6 (2.3) 
   
Head circumference at Birth (cm) *   
   Mean (SD) 33.4 (2.0) 33.3 (1.4) 
   
Birth Order (%)   
   1 41 (33) 59 (47) 
   2 44 (35) 24 (19) 
   3 24 (19) 32 (25) 
   ≥4 17 (14) 12 (10) 
   
 





Table 3-2 Family history of allergic diseases 
 
 Placebo  
n = 126 (%) 
Probiotic  
n =127 (%) 
   
Family history of asthma 51 (41) 59 (47) 
   Father 19 14 
   Mother 22 38 
   Siblings 16 12 
   
Family history of allergic rhinitis  87 (69) 92 (72) 
   Father 38 38 
   Mother 53 62 
   Siblings 19 9 
   
Family history of eczema  41 (33) 39 (31) 
   Father 13 13 
   Mother 20 15 
   Siblings 18 15 
   
Maternal atopy 77 (61) 87 (69) 
   
Paternal atopy 53 (42) 52 (41) 
   
Atopy in both parents 24 (19) 19 (15) 
   
 
















The total monthly family incomes, parents’ highest level of education and housing 
types of the 2 groups were similar (Table 3.3). A total of 151 (60%) families had total 
monthly income less than the 2nd quartile of $3999 (59% in placebo and 61% in 
probiotic group). About half of either parent had completed tertiary education (55% in 
placebo and 57% in probiotic group) and most (87%) of the families are staying in 
public housing (88% in placebo and 85% in probiotic group). 
 
Table 3-3 Parents’ Particulars 
 
 Placebo 
 n = 126 (%) 
Probiotic 
 n =127 (%) 
   
Total monthly family income    
   1st quartile : Below $2000 36 (29) 38 (30) 
   2nd quartile : $2000-$3999 38 (30) 39 (31) 
   3rd quartile : $4000-$5999 22 (17) 23 (18) 
   4th quartile : More than $6000 30 (24) 27 (21) 
   
Father’s highest level of education completed    
   Primary 8 (6) 8 (6) 
   Secondary 57 (45) 51(40) 
   Tertiary 61 (49) 68 (54) 
   
Mother’s highest level of education completed    
   Primary 11 (9) 5 (4) 
   Secondary 56 (44) 63 (50) 
   Tertiary 59 (47) 59 (46) 
   
Type of housing    
   Public housing 111 (88) 108 (85) 
   Private apartments (Condominium) 10 (8) 15 (12) 
   Landed property 5 (4) 4 (3) 






The post-natal histories of the 2 groups were also similar (Table 3.4). Two subjects in 
the probiotic group were admitted to neonatal intensive care unit (ICU). One of the 3 
subjects in the placebo group who was admitted to special care nursery and 3 other 
subjects (2 placebo and 1 probiotic subjects) who were admitted to the post-natal 
ward were given antibiotics. Post-natal complications were reported for 16 (6%) 
subjects (7 in placebo group: mild aspiration, 2 infants of group B streptococcus 
colonised mothers, pethidine-induced neonatal depression, small for gestational age, 
suspected sepsis/viral pneumonia/jaundice and swallowed blood syndrome; 9 in 
probiotic group: Unknown infection, ABO incompatibility, rhesus positive, 
hypoglycaemic, transitory tachypnea of newborn, insulin-dependent diabetes mellitus, 
pre-term, respiratory depression and shallow breathing at delivery. As these post-natal 
complications resolved quickly, these subjects were included into the study except for 
one who was withdrawn by the investigator as the mother was found to be a drug 
abuser and deemed unsuitable for the study. A pre-term baby of 34 weeks gestation 
age was inadvertently included in the study and followed up on an intention to treat 
basis although the child did not meet eligibility criteria of gestational age above 35 
weeks. Most of the abnormalities reported at birth were minor, such as soft systolic 
murmur, G6PD deficiency and haemangioma over the face, and were not deemed to 
interfere with the study except for 1 subject diagnosed with Fallot’s tetralogy in the 
placebo group and 1 subject with congenital liver disease in the probiotic group who 









Table 3-4 Subjects’ Post-Natal History 
 
 Placebo  
n = 126 (%) 
Probiotic  
n =127 (%) 
   
Admission    
   Post-natal ward 123 (98) 119 (94) 
   Special Care Nursery 3 (2) 6 (5) 
   Neonatal ICU 0 (0) 2 (1) 
   
Use of antibiotics    
   Yes 3 (2) 1 (1) 
   No 123 (98) 126 (99) 
   
Post-natal complications    
   Yes 7 (6) 9 (7) 
   No 119 (94) 118 (93) 
   
Abnormality    
   Heart 4 (3) 4 (3) 
   Respiratory 0 (0) 0 (0) 
   Abdominal 1 (1) 1 (1) 
   Neurologic 1 (1) 0 (0) 
   Others * 13 (10) 11 (9) 
   
 
* Others include cephalohaematoma, congenital dislocation of the hips, haemangioma, 
erythema toxicum neonatorum, supernumerary nipple, acrocyanosis, caput 














3.3.2 Feeding history 
 
The compliance level of consuming at least 60ml of trial formula per day from birth 
to 6 months was 89% in the probiotic group and 85% in the placebo group. All 
subjects did not consume any other probiotic preparations or dietary products during 
the 6 month intervention period.  
 
At the end of the 6 months supplementation period, only 2% in the placebo and 3% in 
the probiotic group had near total breastfeeding with at least 60ml of trial formula. 
Majority of the subjects had some breastfeeding combined with formula feeding (77% 
in placebo and 65% in probiotic group). The details of the feeding history are shown 
in Table 3.5.  
 
All subjects had been weaned by 12 months and the median age of weaning to semi-
solids was 6 months for both groups (Table 3.6). All but one or two subjects in each 
group had egg yolk, egg white, fish and soy products while only about 87% in the 














Table 3-5 Feeding history  
 
 
* Five subjects in the placebo group and 3 subjects in the probiotic group withdrew from 
study before follow-up and were excluded from analysis 
 
† Four subjects (3 placebo, 1 probiotic) not assessed at Month 3 & 6 & 12; 4 subjects (3 
placebo, 1 probiotic) not assessed at Month 6 & 12;  2 placebo group subjects not assessed 
at Month 12 and a further 4 subjects (1 placebo, 3 probiotic) not assessed at Month 24 due 





 n = 121 (%) 
Probiotic 
 n =124 (%) 
Feeding history- Birth to Month 6  *   
   Near total breastfeeding with at least  
   60ml of trial formula for 6 months 
2 (2) 4 (3) 
   Any breastfeeding 93 (77) 81 (65) 
   Total formula 26 (21) 39 (32) 
   
Feeding status †   
Month 1   
    Near total breastfeeding with ≥ 60ml of formula 22 (18) 22 (18) 
   Breastfeeding and formula feeding 70 (58) 60 (48) 
   Total formula feeding 29 (24) 42 (34) 
   
Month 3   
    Near total breastfeeding with ≥ 60ml of formula 11 (9) 15 (12) 
   Breastfeeding and formula feeding 44 (36) 36 (29) 
   Total formula feeding 63 (52) 72 (59) 
   
Month 6   
   Total breastfeeding with at least 60ml  6 (5) 10 (8) 
   Breastfeeding and formula feeding 24 (21) 24 (20) 
   Total formula feeding 85 (74) 88 (72) 
   
Month 12   
   Total breast feeding 0 (0) 2 (2) 
   Breastfeeding and formula feeding 10 (9) 10 (8) 
   Total formula feeding 103 (91) 110 (90) 
   
Month 24   
   Breastfeeding and formula feeding 5 (4) 5 (4) 
   Total formula feeding 107 (96) 114 (96) 





Table 3-6 Weaning Practices  
 
 Placebo  
n = 114  
Probiotic  
n =122  
   
Weaned (%)  † 114 (100) 122 (100) 
   < 4 months 2 (1.8) 5 (4.1) 
   4 - 6 months 107 (93.9) 105 (86.1) 
   > 6  - 12 months  5 (4.3) 12 (9.8) 
Age at weaning (months)   
   Mean (SD) 5.6 (0.9) 5.7 (1.2) 
   Median (Range) 6.0 (3.0 to 9.0) 6.0 (1.0 to 12) 
      
Taken egg yolk  113 (99) 120 (98) 
Age at taking egg yolk (months)   
   Mean (SD) 9.7 (3.1) 9.5 (3.4) 
   Median (Range) 10 (4.0 to 21.0) 9.0 (5.0 to 23.0) 
   
Taken egg white  113 (99) 120 (98) 
Age at taking egg white (months)   
   Mean (SD) 10.6 (3.2) 10.2 (3.3) 
   Median (Range) 11.0 (4.0 to 21.0) 10.0 (6.0 to 23.0) 
   
Taken fish  112 (98) 120 (98) 
Age at taking fish (months)   
   Mean (SD) 7.6 (2.6) 7.8 (2.7) 
   Median (Range) 7.0 (4.0 to 22.0) 7.0 (4.0 to 18.0) 
   
Taken soy products  113 (99) 119 (98) 
Age at taking soy products 
(months) 
  
   Mean (SD) 9.4 (3.6) 9.7 (3.4) 
   Median (Range) 9.0 (3.0 to 24.0) 9.0 (3.0 to 24.0) 
   
Taken peanuts  99 (87) 101 (83) 
Age at taking peanuts (months)   
   Mean (SD) 15.0 (4.5) 15.0 (4.1) 
   Median (Range) 15.0 (6.0 to 24.0) 14.0 (6.0 to 24.0) 
   
 
† 17 subjects (12 placebo and 5 probiotic) not assessed due to withdrawal of 









3.3.3 Effects of Probiotic Supplementation on Eczema and Allergen 
Sensitization in Interim Analysis at the Age of 1 Year 
 
 
At 1 year of age, interim analysis was performed and the incidence of eczema in the 
probiotic (n = 27/124; 22%) group was similar to that in placebo (n = 30/121; 25%) 
[adjusted OR (ORadj) = 0.82; 95% CI = 0.44 to 1.52]. In subjects with eczema, the 
median SCORAD score at 12 months was 17.10 in the probiotic group and 11.60 in 
the placebo (p=0.17).  
 
Rate of sensitization to common allergens (probiotic = 24.2% vs placebo = 19.0%, 
ORadj = 1.43; 95% CI = 0.76 to 2.70) showed no difference (Table 3.7). Subjects in 
the probiotic group had slightly higher rate of sensitization to dietary (5.6% vs. 5.0% 
in the placebo) and inhalant (19.5% vs. 16.5% in the placebo) allergens compared to 
subjects in the placebo group. The 1 year old serum total IgE geometric mean (95% 
CI) was 18.76 (12.54 to 24.98) kU/L in the probiotic group and 23.13 (16.01 to 30.24) 
kU/L in the placebo (p=0.15).  
 
Atopic eczema (with sensitization) in the probiotic (7.3%) group was similar to that in 










3.3.4 Effects of Probiotic Supplementation on Eczema and Allergen 
Sensitization at 2 Years of Age 
 
 
At 2 years of age, the cumulative incidence of eczema in the probiotic (n = 27/124; 
22%) group was similar to that in placebo (n = 32/121; 26%) (ORadj = 0.73; 95% CI 
= 0.39 to 1.34). The proportions of children without eczema by the age of 2 years are 
similar in the 2 groups (p = 0.38 by log-rank test) presented as Kaplan-Meier curves 
in Figure 3.4. In subjects with eczema, the median most severe SCORAD score by 24 
months was 17.70 in the probiotic group and 17.40 in the placebo (p=0.307) (Table 
3.8). Atopic eczema (with sensitization) in the probiotic (n=9/118; 7.6%) group was 
not significantly different from that of placebo group (n=13/111; 11.7%) (ORadj = 
0.53; 95% CI= 0.20 to 1.38). 
 
Rate of sensitization to common allergens at 2 years of age was not significantly 
different between subjects in probiotic (18.6%) and placebo (18.9%) group (ORadj = 
0.92; 95% CI = 0.46 to 1.84) (Table 3.7). In contrast to the rate of sensitisation in 
Year 1, the subjects in the probiotic group had slightly lower rate of sensitization to 
dietary (3.4% vs. 4.5% in the placebo) and inhalant (16.9% vs. 17.1% in the placebo) 
allergens compared to those among subjects in the placebo group at 2 years of age. 
Peanut and shrimp allergens were added to the skin prick test panel at 2 years old. In 
the probiotic group, 2 subjects had skin prick test reactivity to both peanut and shrimp 
while 1 subject was sensitized to only shrimp. In the placebo group, only 1 subject 
was sensitized to peanuts and no shrimp sensitisation was observed.  
 
Longitudinal changes in skin-prick test reactivity over the 1 year period were 





dust mite allergens Blomia tropicalis who decreased by about three-fold from 1 year 
to 2 years of age in both groups (Figure 3.3). Among the 82 subjects (37 in placebo, 
45 in probiotic group) who had positive skin prick test at either month 12 or month 24 
visit, only 14 subjects (7 in each group) were sensitized to any allergens at both visits. 
Nineteen subjects (10 in placebo, 9 in probiotic) ever had positive test for dietary 
allergens and only 3 (1 in placebo, 2 in probiotic) were found to be sensitized to 
dietary allergens at both visits. Seventy-five subjects (33 placebo and 42 probiotic) 
ever had positive test for inhalant allergens and only 8 (6 placebo and 2 probiotic) had 
skin prick test reactivity at both visits. The differences in the rate of sensitization to 
any allergens between two groups remained insignificant after adjusting for gender, 
birth order, prenatal smoking exposure and feeding history. 
 
 
Amongst the 18 subjects (9 in placebo and probiotic groups each) sensitized to dietary 
allergens at 1 and 2 years of age (Table 3.7), only 2 subjects in the placebo and 1 
subject in the probiotic group were observed to manifest symptoms of food allergy. 
The subject in the probiotic group was found to be sensitized and allergic to egg, 
peanut, fish and shellfish in the 2 years follow-up period. In the placebo group, 1 
subject was allergic to egg white but was outgrown by 2 years old. Another subject in 





Table 3-7 Sensitization characteristics of study subjects at 1 and 2 years of age  
 
 1 year old 2 year old # † 
 Placebo (n = 121) Probiotic (n =124)* Placebo (n = 112) Probiotic (n =119) 
Allergen Sensitization (%)     
Positive skin prick test (any)  23 (19.0) 30 (24.2) 21 (18.9) 22 (18.6) 
     
Dietary allergens (any)  6 (5.0) ** 7 (5.6) 5 (4.5) 4 (3.4) 
    Cow’s milk 0 0 0 1 
   Egg white 6 6 3 2 
   Egg yolk 4 4 0 1 
   Soy 0 0 1 0 
   Peanut Not done Not done 1 2 
   Shrimp Not done Not done 0 3 
     
Inhalant allergens (any) 20 (16.5) 24 (19.5) 19 (17.1) 20 (16.9) 
     Dermatophagoides pteronyssinus  17 20 19  18  
     Blomia tropicalis 18 19 6  5  
     
 
*Skin prick test not performed for 1 subject in probiotic group 
** One subject in placebo group not assessed for dietary allergens 
# 22 subjects (14 placebo, 7 probiotic) not assessed due to withdrawal of consent / withdrawal by investigator / lost to follow up were excluded 
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30 subjects (24.2%) 
 
Sensitized at both visits : 7 (6.3%) 
 
New + : 14 ( 12.5%) 
 
Sensitized at both visits : 7 (5.8%) 
 
New + : 15 (12.6%) 
 
Dietary allergens (any) 
Placebo 
 




7 subjects (5.6 %) 
 
Sensitized at both visits : 1 (0.9%) 
 
New + : 4 ( 3.6%) 
 
Sensitized at both visits : 2 (1.7%) 
 
New + : 2 (1.7%) 
 
Inhalant allergens (any) 
Placebo 
 




24 subjects (19.5%) 
 
Sensitized at both visits : 6 (5.4%) 
 
New + : 13 ( 11.6%) 
 
Sensitized at both visits : 2 (1.7%) 
 






Figure 3-4 Kaplan Meier curves for children without eczema in the probiotic and 


























































Table 3-8 Details of subjects with eczema by 2 years of age  
 
 Placebo (n = 121) Probiotic (n =124) 
   
Ever eczema by 24 mo (%)*   
   Yes 32 (26.45) 27 (21.77) 
   No 89 (73.55) 97 (78.23) 
   
For those with eczema:   
Age at first diagnosis (months)   
   Mean (SD) 5.78 (5.68) 5.54 (4.26) 
   Median (Range) 3.5 (1 to 24) 6 (1  to 20) 
   
Most severe SCORAD by 24 mo, n † 31 25 
   Mean (SD) 18.79 (13.50) 20.45 (9.74) 
   Median (Range) 17.40 (3.9 to 75.0) 17.70 (7.9 to 43.4) 
   
 
* 8 subjects (5 placebo, 3 probiotic) without any clinical assessment after randomisation due 
to withdrawal of consent / withdrawal by investigator / lost to follow up were excluded 
 
† 2 subjects (1 placebo, 1 probiotic) were first diagnosed of eczema during external clinic 
visit and hence no SCORAD was captured. One subject in probiotic group with SCORAD 


























3.3.5 Assessment of confounding factors 
 
Apart from the imbalances in gender and birth order between the probiotic and 
placebo group, differences were also noted for prenatal smoking exposure and feeding 
history from the list of confounding factors recorded (Table 3.9). Multivariable 
logistic regression was performed to account for the possible confounding effects that 
may influence atopic propensity. Adjustment for imbalance of gender, birth order, 
prenatal smoking exposure and feeding history between treatment groups did not 






















Table 3-9 Prevalence of potential confounding factors 
 
 Placebo (n = 126) Probiotic (n =127) 
   
Prenatal Smoking exposure (%)   
  Prenatal maternal smoking 6 (5) 9 (7) 
  Passive smoke exposure in household 46 (37) 58 (46) 
   
Household Passive Smoke exposure by 
Month 6 (%) † 
50 (41) 48 (39) 
   
Keep pets (%) 27 (21) 31 (24) 
   Dogs/Cats   17 (13.5) 17 (13.4) 
   
Type of housing (%)   
   Public housing 111 (88) 108 (85) 
   Private housing (Condominium) 10 (8) 15 (12) 
   Landed property 5 (4) 4 (3) 
   
Feeding history-Birth to Month 6(%) †   
   Near total breastfeeding with at least  
   60ml of formula for 6 months 
2 (2) 4 (3) 
   Any breastfeeding 93 (77) 81 (65) 
   Total formula 26 (22) 39 (32) 
   
Age at weaning (months) †   
   Mean (SD) 5.6 (0.9) 5.7 (1.1) 
   
Use of antibiotics by Month 6 (%) † 13 (11) 10 (8) 
   
Day care attendance by Month 12 (%) † 2 (2) 2 (2) 
   
Day care attendance by Month 24 (%) † 21 (17.4) 23 (18.5) 
   
 
† Five subjects in the placebo group and 3 subjects in the probiotic group withdrew 










3.3.6 Family History and Predictive Capacity of Elevated Cord Blood 
Total IgE Associated with Eczema and Sensitization at 1 Year of 
Age 
 
Elevated cord blood total IgE (≥ 0.5 kU/L) was observed in 107 subjects out of 215 
(49.8%) infants, whose cord blood was collected. But high cord blood total IgE was 
not found to be a risk factor for development of eczema (ORadj = 1.05; 95% CI = 
0.53 to 2.10) and allergen sensitization (ORadj = 1.47; 95% CI = 0.68 to 3.11) at 1 
year of age. Elevated cord blood IgE values were cut off at the level of 0.5 kU/L 
according to the previous reference cut off value [238, 239]. 
 
Maternal atopy and mother with history of eczema were not found to be a risk factor 
for eczema and allergen sensitization at 1 year of age. Paternal eczema was instead 
significantly associated. Although paternal atopy was not found to be a risk factor but 
subjects with paternal history of eczema were 3.02 times more likely to develop 
eczema and 2.79 times more likely to be sensitized to allergens. Adjusted analyses 
accounting for gender, ethnicity, birth order, smoking, mode of delivery, housing type, 
parents’ education, pets at birth, treatment and feeding history were made. These risk 














Table 3-10 Evaluation of risk factors associated with eczema and sensitization at 1 
year of age 
 
Risk factor Eczema Allergen Sensitisation 
 ORadj (95% CI) ORadj (95% CI) 
   
Cord blood IgE ≥ 0.5 kU/L † 
(n=107)  1.05 (0.53 – 2.10) 
 
1.47 (0.68 – 3.11) 






0.77 (0.38 – 1.54) 
 
0.86 (0.41 – 1.80) 
Mother with Eczema 
(n=32) 0.85 (0.33 – 2.19) 0.79 (0.28 – 2.22) 






1.38 (0.71 – 2.66) 
 
0.61 (0.30 – 1.26) 
Father with Eczema (n=26) 3.02 (1.18 – 7.76) 2.79 (1.02 – 7.66) 
 
*Adjusted with gender, race, birth order, smoking, mode of delivery, housing type, parents’ 
education, pets at birth, treatment and feeding history. 
 















3.3.7 Subset analysis at 2 years of age 
3.3.7.1  Mode of delivery 
 
The incidence of eczema at 2 years of age in caesarean-delivered children 
supplemented with probiotics was lower in the probiotic (n = 5/34; 14.7%) group as 
compared to that in placebo group (n = 8/32; 25%) although this difference did not 
reach statistical significance (ORadj = 0.33; 95% CI = 0.07 to 1.42, p=0.135). The 
rate of allergen sensitisation was similar in this subset of children with 12.5% (n=4/32) 
sensitized to any allergens in the probiotics group and 13.8% (n=4/29) sensitized in 
the placebo group (ORadj = 0.62; 95% CI = 0.10 to 3.68).  Atopic eczema (with 
sensitization) in the probiotic (9.4%, n=3/32) group was also found to be similar to 
that in placebo group (10.3%, n=3/29) (ORadj = 0.58; 95% CI= 0.07 to 4.48) in these 
caesarean-delivered children. 
 
In the normal vaginal delivered infants, the incidence of eczema in the probiotics 
group (n= 22/90; 24.4%) was similar to that in the placebo group (n= 24/89; 27.0%) at 
2 years of age (ORadj = 0.80; 95% CI = 0.39 to 1.64). There was no significant 
difference in the rates of sensitization between the probiotic (n = 18/86; 20.9%) and 
placebo group (n= 17/82; 20.7%) in this subset of infants (p = 0.804). Vaginally 
delivered subjects with atopic eczema (with sensitization) in the probiotic (n=6/86; 
7.0%) group was less than that in the placebo (n=10/82; 10.2%) although this 









3.3.7.2  Maternal Atopy 
 
Similarly, the incidence of eczema in a subset of children with atopic mothers was not 
statistically different in the probiotic (n = 19/85; 22.4%) group as compared to that in 
placebo (n = 17/74; 23.0%) (ORadj = 0.88; 95% CI = 0.41 to 1.92). The rate of 
allergen sensitisation in this subset of children in the probiotics group (n=11/81; 
13.6%) was lower than that in the placebo (n=14/65; 21.5%) group but not 
significantly different (ORadj = 0.53; 95% CI = 0.21 to 1.33).  Atopic eczema (with 
any positive skin prick test) in the probiotic (9.4%, n=3/32) group was similar to that 
in placebo (10.3%, n=3/29) (ORadj = 0.58; 95% CI= 0.07 to 4.48) in these children 
with maternal atopy. 
 
3.3.7.3  Feeding History 
 
To address the variability in probiotic dose resulting from variations in patterns of 
breast feeding within the intervention group and eczema outcome, analysis of the data 
according to the amount of probiotic supplemented formula used was made and 
although a linear increasing trend of 15.4% to 22.2% to 75.0% of subjects with 
eczema was observed with corresponding decreasing dose of probiotics from fully 
formula-fed to partially breastfed to near total breast feeding with at least 60ml of trial 
milk formula for 6 months, the linear trend observed was not found to be significant 
with p = 0.05266 (Table 3.11). Further comparison of subjects who were on total 
formula feeding in the probiotic and placebo group also did not show an effect of high 






Table 3-11 Feeding history (%) of subjects with eczema  
 
  Feeding history-Birth to Month 6 (%) 
  Near total breastfeeding with at 
least 60ml of formula 
Partial breastfeeding Total formula feeding 





Yes 1 (50.0) 3 (75.0) 23 (24.7) 18 (22.2) 8 (30.8) 6 (15.4) 





3.3.8 Effects of Probiotic Supplementation on Asthma and Allergic 
Rhinitis at 2 Years of Age 
 
There was no difference in the incidence of asthma (according to definition of ≥ 3 
episodes of wheeze) in the probiotic (n=11/124; 8.9%) and that in placebo group 
(n=11/121; 9.1%)  (ORadj = 1.15; 95% CI= 0.46 to 2.87) at 2 years of age. The 
median age at first diagnosis of asthma was 18 months for subjects in the probiotic 
group and 15 months for subjects in the placebo group. The incidence of allergic 
rhinitis was not significantly different between the two groups (n=2/124; 1.61% vs. 
n=3/121; 2.48% in the placebo, p=0.86). The adjusted OR was 0.84 (95% CI: 0.13 to 
5.54). The median age at first diagnosis of allergic rhinitis in the subjects was 12 
months for probiotic and 17 months for placebo groups. Adjusted analyses accounting 
for imbalance of gender, birth order, prenatal smoking exposure and feeding history 
did not alter the results significantly (Table 3.12). 
 
The coexistence of more than one atopic conditions was observed in 4.1% (n=5/121) 
of the placebo and 3.2% (n=4/124) of the subjects in the probiotic group (p= 0.747). 
In both groups, only 1 subject was diagnosed with all 3 atopic diseases, namely 
eczema, asthma and allergic rhinitis. Figure 3.5 shows that only 1 subject in the 
placebo group and none in the probiotic group reported having symptoms of both 
asthma and allergic rhinitis at 2 years of age. Two subjects in both the placebo and 







Table 3-12 Prevalence of asthma and allergic rhinitis at 2 years of age  
 
 Placebo  
(n = 121) 
Probiotic 
 (n =124) 
   
Ever asthma† (%)*   
   Yes 11 (9.09) 11 (8.87) 
   No 110 (90.91) 113 (91.13) 
   
For those with asthma:   
Age at first diagnosis (months)   
   Mean (SD) 14.18 (6.18) 16.09 (5.96) 
   Median (Range) 15 (3 to 24) 18 (6 to 24) 
   
Ever allergic rhinitis# (%)*   
   Yes 3 (2.48) 2 (1.61) 
   No 118 (97.52) 122 (98.39) 
   
For those with rhinitis:   
Age at first diagnosis (months)   
   Mean (SD) 14.33 (10.26) 12 (8.48) 
   Median (Range) 17 (3 to 23) 12 (6 to 18) 
 
* 8 subjects (5 placebo, 3 probiotic) without any clinical assessment after randomisation due 
to withdrawal of consent / withdrawal by investigator / lost to follow up were excluded 
 
†Asthma - 3 episodes of nocturnal cough with sleep disturbances or wheezing, separated by at 
least seven days, in a setting where asthma was likely and conditions other than allergy have 
been excluded 
 
#Allergic rhinitis - rhinorrhea, nasal obstruction, nasal itching and sneezing which were 












Figure 3-5 Incidence of multiple atopic conditions in the placebo and probiotic 
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This randomized controlled trial, a first in an Asian at risk cohort, did not show a 
protective effect of probiotic supplementation for the first 6 months of life on eczema, 
asthma, allergic rhinitis or allergen sensitization at 1 and 2 years of age. To date there 
have been 6 published clinical trials on the role of early life probiotic supplementation 
on the primary prevention of eczema.  These studies are summarized in Table 1.5.  
Our findings are similar to 2 other clinical trials, one involving an Australian cohort 
(n=178) [167, 168] and a second German cohort (n=94) [171]. These studies in fact 
reported negative outcomes.  The Australian study showed that allergen sensitization 
was increased in those who received probiotics, and both studies showed an increased 
frequency of recurrent wheezy bronchitis.  The data from these studies suggest that 
probiotic supplementation in early life may not be altogether innocuous.  Similar to 
what we observed in our study, this German study [171], a New Zealand study [173] 
and 3 other published Scandinavian trials [8, 165, 169] showed that probiotics did not 
have an effect on allergen sensitization.  The Scandinavian trials, however, 
demonstrated a reduction in eczema at 2 years, although the Swedish study by 
Abrahamsson et al. (n=188) showed this benefit only in the subset of IgE-associated 
eczema [169].  Only one study (n=132) has published 7 years long-term follow up 
results [163, 164] and has shown a sustained benefit in terms of eczema prevalence, 
but similar to our study at 2 years, the results were disappointing with regards to 
respiratory allergies.   
 
In subset analysis of interactions between mode of delivery and probiotic intervention, 
caesarean-delivered babies supplemented with probiotics did not show a significant 





study although the incidence of eczema at 2 years of age in caesarean-delivered 
children supplemented with probiotics was about 40% lower in the probiotic (14.7%) 
group as compared to that in placebo (25%). An increase in sample size could 
increase the power to possibly detect a statistical difference between the 2 groups. The 
follow-up study of one of the Scandinavian trial (Kukkonen et al. [165]) to 5 years of 
age demonstrated that probiotics prevented cumulative IgE associated allergic 
diseases, in particular IgE associated eczema and positive food skin prick test 
response and/or food-specific IgE > 0.7 kU/L, in caesarean-delivered children but not 
in the total cohort [166]. It has been shown that vaginally delivered babies are 
colonized with bifidobacteria and lactobacilli earlier than caesarean-delivered babies 
[43, 44]. Furthermore, children born by means of caesarean section was found to be 
associated with an increased risk of developing respiratory allergies [45]. The 
deprivation of the massive microbial load during vaginal delivery might be substituted 
by probiotic supplementation.  
 
Besides differences in population characteristics between these clinical trials, 
variations in study design may have also contributed to the observed differences.  A 
common difference in the study designs of 2 studies (our study and Taylor et al.) that 
failed to observe a protective effect of probiotics on eczema was the absence of 
prenatal probiotic supplementation in these protocols.  Prenatal supplementation may 
therefore be an important factor in conferring these benefits.  Supplementation of L. 
rhamnosus GG to the mothers antenatally enhanced specific changes in the transfer 
and colonisation of bifidobacteria in neonates [216]. Furthermore, in the Swedish 
study by Abrahamsson et al. [169], prenatal supplementation resulted in a more 





with atopic mothers. This study found that probiotic supplementation with L. reuteri 
during late pregnancy reduced breast milk levels of TGF-ß2 and increased IL-10 
[217]. Different strains of probiotics can have varying immunomodulatory effects as 
Prescott et al. observed on the contrary that L. rhamnosus HN001 or B. lactis HN019 
prenatal supplementation increased breast milk levels of TGF-ß1 and IgA [218]. This 
observation was in consistent with Rautava et al. study which showed higher TGF-ß2 
isoform with no difference in TGF-ß1 in the breast milk of women who received L. 
rhamnosus GG [219]. Animal studies suggested that TGF-ß in breast milk may have 
anti-inflammatory effects [220] and induces allergen-specific tolerance [221]. The 
advantage of prenatal supplementation of probiotics has been further highlighted by 
the presence of small quantities of viable bacteria with a range of bacterial DNA 
signatures in breast milk and greater biodiversity of maternal peripheral blood 
mononuclear cells which could program the neonatal immune system [222]. Prenatal 
supplementation of L. rhamnosus GG to mothers was also found to promote newborn 
colonization with L. rhamnosus GG for as long as 6 months and may even persist to 
24 months [223]. Consumption of L. rhamnosus GG by pregnant mothers was further 
showed to increase the bifidobacterial diversity in infants with more B. breve and 
lesser B. adolescentis than the placebo group [216]. However, prenatal 
supplementation in the German study did not result in a positive outcome. This could 
further suggest that probiotics supplementation to mothers in late pregnancy is of 
crucial importance.  
 
The different probiotic strains studied and their doses may also contribute to the 
inconsistency in results between studies. Our study utilized a combination of B. 





gastrointestinal tract. Immunostimulatory oligodeoxynucleotides which suppress IgE 
and Th2 cytokines production have been identified in these probiotic strains [224, 
225]. Furthermore, B. longum BB536 has been reported to have a treatment effect on 
Japanese cedar pollinosis [151, 152]. It was therefore postulated that the combination 
of these 2 probiotic bacteria in our study may provide additive immunomodulatory 
effects.  It has been further shown that the supplementation of these bacterial strains 
in infant formula is well tolerated [190].  The L. rhamnosus LPR strain used in our 
study has been found to be indistinguishable from L. rhamnosus GG using specific 
molecular probes targeted at 16sRNA (personal communication, F Rochat, Nestle, 
Lausanne, Switzerland).  Additionally, L. rhamnosus LPR was originally derived 
from a product, Dicoflor® which contains L rhamnosus GG (ATCC 53103) 
(Certificate of Receipt, China General Microbiological Culture Collection Center), 
indicating that both these probiotic bacteria are identical.  Lactobacillus rhamnosus 
GG has shown benefits on eczema most consistently with 2 studies reporting positive 
effects [8, 163-165]. However, the inclusion of L. rhamnosus in our study, as well as 
the German study did not result in the same benefits. The New Zealand study that 
used L. rhamnosus HN001 and B. animalis subsp lactis strain HN019 demonstrated 
that L. rhamnosus HN001 supplementation but not B. animalis subsp lactis could 
reduce the prevalence of eczema with no effect on allergen sensitization [173].  The 
only study (Taylor et al.) that used L. acidophilus for supplementation resulted in 
increased allergen sensitization in the supplemented subjects. Another study 
(Kukkonen et al.) used a mixture of 4 probiotics with prebiotic galacto-
oligosaccharides and showed a reduction in eczema and atopic eczema. There is 
however still insufficient evidence to determine the role of prebiotics in allergy 





a lost to follow up rate of  20%. Another study [227], which did not select infants at 
risk of allergy, reported no significant difference in eczema in infants up to four 
months of age. Meta-analysis of these 2 studies could not determine the role of 
prebiotics in the prevention of eczema due to the heterogeneity of the study design 
[228].   
 
Our study involved a relatively lower dose of probiotics (approximately 2 logs) 
compared to the other primary prevention trials which reported protective effects on 
eczema [8, 163-165]. However at these lower doses, we did document consistent 
transit of the supplemented probiotic in the stools of infants in the probiotic group 
compared to placebo [229, 230]. Significantly more L. rhamnosus (OR= 111.93; 95% 
CI = 23.18 to 540.45, p < 0.001) and B. longum (OR= 3.75; 95% CI = 1.27 to 11.07, 
p= 0.017) were detected by polymerase chain reaction method in the probiotic group 
over the first 3 months of supplementation [229].  Furthermore, the viability of this 
strain combination in the milk formula was monitored at the end of the study period to 
ensure preservation of bacterial viability at the required dose.  
 
A unique feature of our protocol was the supplementation of probiotics in infant 
formula.  We felt that this was consistent with the situation in “real-life” as a large 
proportion of our mothers and within and outside Asia, either supplement breast 
feeding with infant formula [231] or use infant formula only. Furthermore, 
supplementation in formula would improve compliance.  To address the variability in 
probiotic dose resulting from variations in patterns of breast feeding within the 
intervention group and eczema outcome, analysis of the data according to the amount 





was made and a near to significance increasing trend of subjects with eczema was 
observed with corresponding decreasing dose of probiotics (p = 0.05266). The 
difference might have been detected with a larger sample size to increase the 
statistical power of the study. In this trial we resolved to use standard infant cow’s 
milk formula rather than a hypoallergenic formula so as to avoid an added parameter 
that might confound atopy development [232].  It is also not a practice to use 
hydrolyzed formula in at risk infants in Asian communities including ours.  Of great 
interest was the absence of cow’s milk sensitization (except 1 in the probiotic group at 
2 years old) or clinical cases of cow’s milk allergy despite exposure in our cohort. 
 
Another interesting point was that the prevalence of eczema in our cohort (26%) was 
lower than the 39% in the placebo group at 1 year [167] and 46% at 2 years [8] in the 
other studies. Despite this lower observed prevalence of eczema (26%), our study was 
not underpowered as we could still detect a relative reduction of eczema of 50%, with 
a power of 80%.  Interestingly, the German study also reported relatively low rates of 
eczema (28%).  It may be possible that probiotics are ineffective in a population with 
lower rates of eczema. The reasons for the lower prevalence of eczema are almost 
certainly multifactorial and would include the different genetic make-up and its 
interaction with lifestyle and the environment. These findings are nonetheless 
consistent with the ISAAC Phase 3 studies where the cumulative prevalence of 
eczema in schoolchildren in the Singapore cohort (8.2%) was significantly lower than 
those reported in Australia (32.3%) and in Scandinavia (38.6%) where the other 






Allergic airway diseases usually manifest later in life and in our study the low 
prevalence of 9% asthma and 2.5% allergic rhinitis at 2 years of age did not yet allow 
for their comparison. An additional follow-up period will be critical for the evaluation 
of respiratory allergies in the form of clinical asthma, allergic rhinitis and 
sensitization to inhalant allergens. These tend to develop later in life after the age of 2 
years and this step-wise, temporal development of respiratory allergies has been 
described as the “Atopic March” [234-236].  Thus only a small proportion of subjects 
with atopic symptoms had symptoms for more than one atopic condition.  
 
Atopic diseases are multifactorial diseases influenced by various familial and 
environmental factors. Thus identifying useful predictive markers for effective 
screening remains a challenge. Family history and elevated cord blood serum IgE 
[237-239] have been proposed as markers to screen newborns for atopy risk. However, 
the predictive capacity of cord blood IgE has been questioned [240-242] while family 
history of atopy has generally been regarded as a useful predictor. In our study, 
positive family history and elevated cord blood serum IgE were not found to be 
associated to eczema, allergen sensitization, atopic eczema at 1 year of age. 
Combining parental atopy with elevated cord IgE also failed to identify babies at risk 
of eczema and allergen sensitization although these have been demonstrated in other 
studies to be predictors of atopy in newborn babies [238, 239]. In contrast to 
published literature [243-245], maternal atopy and mothers with eczema were not 
found to be a risk factor for eczema. Paternal eczema was instead significantly 
associated. The associations between parents’ atopic disease and the risk of eczema in 
the subjects may vary according to the type of atopic disease with parental eczema 





according to parental gender [246]. It is also possible that questionnaires were usually 
completed by mothers resulting in a misclassification of paternal symptoms. But this 
possibility could be eliminated as this should have a greater regression dilution bias 
observation as opposed to results observed in our study.  
 
In conclusion, our study does not support the role of early life probiotic 
supplementation as a modality for primary eczema prevention. An extended period of 
follow up of this cohort is intended to determine longer term outcomes and effect on 
other manifestations of allergy in this population. Further work is needed to determine 
whether prenatal supplementation, probiotic dose and probiotic strain are important 
considerations. A larger study will have to be performed to increase the power and 












4 Chapter 4: Effect of Probiotic Supplementation on 





Probiotics are promising immunomodulators which enhance innate and adaptive 
immunity in the host [64]. Gnotobiotic animal models have shown that probiotics 
have significant immunomodulatory effects on local and systemic immune responses.  
Furthermore, its safety record in humans has made probiotic supplementation an 
attractive strategy to modulate and enhance the immune system.  Probiotics have been 
conferred GRAS (generally regarded as safe) status by the Food and Agriculture 
Organization(FAO)/World Health Organization expert panel [56], and are considered 
safe in the neonate [84, 85].  Probiotic supplementation in young children has been 
shown to protect against gastrointestinal infections such as rotavirus gastroenteritis 
[117].  Probiotics have also been shown to enhance specific immune responses to 
vaccination in young children and adults.  It increased the immunogenicity of orally 
administered vaccines such as that of rotavirus [86], Salmonella [87], polio [89] and 
cholera [91]; as well as enhanced antibody responses to parenterally administered 
vaccines, namely diphtheria, tetanus, and Haemophilus influenzae type b [93-97].  
Probiotics therefore have an adjuvant effect by enhancing immunogenicity of 
vaccines. This study assessed the effect of probiotic supplementation in the first 6 
months of life on specific IgG antibody responses to Hepatitis B vaccination.  To our 
knowledge, there have been no previous reports on the effect of probiotics on 






4.2  Materials and Methods 
 
4.2.1  Vaccination  
 
Depending on the attending vaccination centre, majority of the infants received either 
1 of 2 schedules of Hepatitis B vaccination with intramuscular injection in the 
anterolateral aspect of the thigh at ages 0, 1 and 6 months respectively, following the 
Singapore national immunization program. Schedule A consisted of monovalent 
Hepatitis B vaccination, (HBVax, MSD, Whitehouse Station, NJ, USA)  at Dose 1 
and 2 (2.5μg each) and a hexavalent diphtheria-tetanus-acellular pertussis (DTPa) 
combination vaccination containing a Hepatitis B component (10μg) (Infanrix HEXA, 
GSK Biologicals, Rixensart, Belgium) at Dose 3.  Schedule B consisted of 
monovalent Hepatitis B (HBVax) 2.5μg/dose for all three doses.  Infants born to 
Hepatitis B surface antigen (HBsAg)-positive mothers received the Hepatitis B 
vaccine with Hepatitis B immune globulin (HBIG) at birth to prevent transmission of 
perinatal Hepatitis B viral infection.  
 
4.2.2 Antibody analysis 
 
Venous blood was collected at 12 months of age and analyzed for Hepatitis B 
serology with measurement of the Hepatitis B virus surface antibody (anti-HBs) 
immunoglobulin G using ADVIA Centaur Anti-HBs (Bayer Health Care, Tarry town, 








4.2.3 Statistical analysis 
 
SPSS software (version 15.0 for Windows) was used to perform independent two-
sample t-test to compare anti-HBs IgG geometric mean titres between placebo and 
probiotic groups. The geometric mean titres were obtained by computing the 
exponentiated values of the arithmetic mean of the logarithm transformed values of 
the anti-HBs IgG titres. The logarithmic transformation gave the data a good fit to the 
normal distribution to enable the use of parametric Student’s t-test [209, 247].  A p 
value of < 0.05 was considered statistically significant for all analyses.  
 
4.3  Results 
4.3.1 Baseline characteristics and participants 
 
Families were assessed at the antenatal clinic and 253 newborns were recruited into 
the study.  During the follow-up period, 3 subjects from the probiotic group and 6 
subjects from the placebo group did not complete the study and blood samples were 
not collected. At the 12-month visit, 11 subjects refused blood taking. There were 20 
subjects who received alternative vaccine schedules (other than schedule A or B) 
involving combination vaccines and these subjects were excluded from analysis. As 
the primary clinical outcome of the study was eczema, vaccine schedule was 
determined by the vaccination centre the subject attended. 
 
The demographic and social characteristics, gender ratio, gestational age, birth weight, 
number of siblings, daycare attendance, smoking at home and breastfeeding rate of 
the 2 vaccine groups were comparable (Table 4.1). There were 11 subjects (4.72%) 
including one born to a Hepatitis B carrier (HBeAg positive) mother, who failed to 





schedule A (probiotic = 2) while 8 received vaccine schedule B (probiotic = 3) 
(Figure 4.1).  Seven of the 11 subjects seroconverted after an additional booster dose 
of vaccine (HBVax, 5 μg), and the eighth subject after 2 doses.  The ninth subject was 
born to Hepatitis B carrier mother failed to respond and was found to be HBsAg 
positive.  The remaining 2 subjects (10th and 11th) refused further blood evaluation. 
 
There were therefore 202 evaluable subjects.  Fifty-seven infants received vaccine 
schedule A (probiotic=29, placebo=28) and 145 infants received vaccine schedule B 






























Others = 6 
EXCLUDED 9 drop-outs  
(probiotic=3 and placebo=6) 
& 
11 who refused blood-taking 
(probiotic=7 and placebo=4) 
 Others = 14 
Schedule B = 73 
Schedule A = 29 
Non-responders= 3 (3.75%) 
Non-responder = 1 (3.45%) 
Non-responders= 5 (6.85%) 
Non-responders = 2 (6.67%)  
PLACEBO 
116 infants 
Schedule A = 31 




Schedule A = HBVax Dose 1 & 2 (2.5ug each), Infanrix HEXA Dose 3 (10ug) 





Table 4-1 Characteristics of the Study Population 
 
 Vaccine Schedule A Vaccine Schedule B 








Gestational age  
in weeks, Mean (SD)  
38.3 (1.6) 38.8 (1.1) 38.5 (1.4) 38.4 (1.1) 
     
Gender      
   Male 12 (41.4) 15 (53.6) 41 (53.2) 40 (58.8) 
     
Birth Weight (kg)     
   Mean (SD) 3.1 (0.5) 3.2 (0.4) 3.2 (0.5) 3.1 (0.4) 
     
Birth Order     
   1 17 (58.6) 10 (35.7) 33 (42.9) 21 (30.9) 
   2 2 (6.9) 12 (42.9) 16 (20.8) 23 (33.8) 
   3 10 (34.5) 4 (14.3) 20 (26.0) 14 (20.6) 
   ≥4 0 (0) 2 (7.2) 8 (10.4) 10 (14.7) 
     
Smoking exposure  10 (34.5) 8 (28.6) 43 (51.2) 29 (39.7) 
     
Day care attendance by 
Month 12  
0 (0) 0 (0) 0 (0) 2 (2.7) 
     
Feeding history-Birth to 
Month 6 
    
   Near total 
breastfeeding with at 
least  
   60ml of formula for 6 
months 
2 (6.9) 1 (3.6) 1 (1.2) 0 (0) 
   Any breastfeeding 19 (65.5) 24 (85.7) 54 (64.3) 54 (74.0) 
   Total formula 8 (27.6) 3 (10.7) 29 (34.5) 19 (26.0) 













4.3.2 Effects of probiotic supplementation on Hepatitis B surface 
antibody response 
 
The seroconversion rates were almost similar between the 2 schedules.  However, of 5 
infants who were born to Hepatitis B carrier mothers, vaccine failure occurred in one 
infant who was randomized to the probiotic group and received Schedule A 
vaccinations.  This child was the only subject to develop the Hepatitis B carrier state.  
 
Within the placebo group, the anti-HBs geometric mean titre (95% CI) of subjects in 
Schedule A [187.97 (180.70 – 195.24) mIU/ml] were lower than that in subjects with 
Schedule B [302.34 (296.31 – 308.37) mIU/ml], although this difference did not reach 
statistical significance (p=0.076). In contrast, within the probiotic group, anti-HBs 
geometric mean titres of those receiving schedule A [345.70 (339.41 – 351.99) 
mIU/ml]  and B [302.06 (296.31 – 307.81) mIU/ml] were comparable (p=0.575).  In 
other words, probiotic supplementation could potentially increase anti-HBs responses 
in those receiving Schedule A to levels more comparable with those in Schedule B.  
Hence, for infants who received Schedule A, the anti-HBs geometric mean (95% CI) 
titres were 345.70 (339.41 – 351.99) mIU/ml in the probiotic group and 187.97 
(180.70 –195.24) mIU/ml in the placebo (p = 0.069). This difference was not 
observed for infants receiving vaccine Schedule B where anti-HBs geometric mean 
(95% CI) titres were very similar [probiotic: 302.06 (296.31 – 307.81) mIU/ml, 
placebo: 302.34 (296.31 – 308.37) mIU/ml] (p = 0.996). The data is summarized in 




































anti-HBs  IgG  
geometric mean 
titre (mIU/ml) 
95% C.I. p value Seroconversion rate (%) p value 
A 
 




probiotics 29 345.70 339.41 – 351.99 93.5 
B 




probiotics 77 302.06 296.31 – 307.81 97.5 
Schedule A: Monovalent HepB vaccines at 0, 1 month and DTPa-IPV-HiB- HepB combination vaccine at 6 months  









Prevention of childhood infections through vaccination is an important target of 
global healthcare.  Hepatitis B vaccination is part of the WHO expanded program of 
immunization.  Many countries have adopted universal Hepatitis B vaccination.  In 
countries where Hepatitis B is endemic, vertical transmission of the infection is still a 
concern. Strategies that may improve immunogenicity of the vaccine are welcomed, 
especially in infants born to Hepatitis B carrier mothers.   
 
Probiotic supplementation has been shown to enhance the immunogenicity of various 
vaccines [86, 87, 89, 91, 93-97].  This study evaluated the effects of probiotics on 
Hepatitis B vaccine responses in infants vaccinated from birth.  Two vaccine 
schedules were compared as the majority of subjects received these schedules.  Our 
results show that the schedule with 3 monovalent doses of Hepatitis B vaccine 
resulted in better anti-HBs responses compared to the schedule consisting of 2 
monovalent doses followed by a third dose as a DTPa combination vaccine, although 
this difference was not statistically different (p=0.076).  These results differ from two 
recent studies conducted in Singapore, where anti-HBs responses involving 
monovalent vaccine and combination vaccine were similar [248, 249].  This observed 
difference may be related to the dose of the monovalent vaccines (2.5μg, half-dose of 
HBVax, MSD in our study vs 10μg, full-dose Engerix B, GSK Biologicals, Rixensart, 
Belgium in previous studies [248, 249]) used between studies, and the combination of 
Hepatitis B vaccines from different manufacturers in schedule A (MSD for 
monovalent and GSK Biologicals for combination vaccine) in our study. These 






There was only one documented vaccine failure in our cohort.  This subject was born 
to Hepatitis B (HBeAg +) mother and despite hyperimmune globulin at birth and 3 
doses of Hepatitis B vaccines, developed the carrier state.  This failure to respond may 
be genetically determined as suggested in a recent report which revealed risk 
haplotypes in the genetic variants of the HLA-DP locus [250]. The remaining 8 
subjects who seroconverted after one or two additional booster doses of vaccination 
should not be considered non-responders as is defined by a failure to seroconvert after 
completion of two full 3-dose series of the Hepatitis B vaccine and for whom an acute 
or chronic Hepatitis B infection has been ruled out [251].  
 
Interestingly, probiotic supplementation in the first 6 months of life could improve 
anti-HBs responses in subjects receiving schedule A (2 doses monovalent + 1 dose 
combination) but not in those receiving schedule B where higher antibody responses 
were observed. The immune response ceiling has possibly been reached in those 
subjects that received Schedule B.  This difference, however, did not reach statistical 
significance.  This is likely to have arisen from the smaller sample size of subjects in 
schedule A, since the vaccine schedules were not randomized for this study but were 
dependent on the vaccine centres attended.  This restriction on sample size could have 
compromised the statistical power of the study, in particular for schedule A. This 
study may be statistically underpowered as the number of subjects receiving vaccine 
schedule A were less than those in vaccine schedule B. Nonetheless, the data suggests 
that probiotics can potentially be used as an adjuvant for immune responses in 






Breastfeeding is unlikely to have influenced the observed differences between groups, 
since only a very small proportion of subjects were totally breastfed apart from the 
study formula (Table 4.1). There were also little differences in breast feeding 
practices between groups. Breastfeeding has shown contrasting results in some studies.  
In a study to evaluate Hib conjugate vaccine response, breastfed infants produced 
higher antibody concentrations than formula-fed infants [252].  In contrast, in another 
Australian study, breastfed infants had lower anti-Hib capsular polysaccharide 
antibody concentrations both before and after immunization with Hib conjugate 
vaccine as compared with formula-fed infants [253].  
 
In conclusion, our data suggests that probiotic supplementation from birth could 
enhance Hepatitis B antibody response in infants receiving certain vaccine schedules.  



















Supplementation of certain strains of probiotics may enhance resistance against 
infections. The potential effects have been studied in day care centres where infants 
are more prone to develop gastrointestinal and respiratory tract infections than 
children at home. These infants supplemented with L. rhamnosus GG for 7 months 
resulted in a lower rate of use of antibiotics for respiratory tract infections and a 0.6 
day shorter absence period due to illness compared to the placebo group, when 
adjusted for age. Another study in infants attending day care centres studied the 
effects of two different probiotics, B. lactis (BB-12) and L. reuteri on prevention of 
infections. Both probiotics reduced the number of days and number of episodes with 
diarrhea and fever (>38 ˚C). Furthermore, L. reuteri but not B. lactis   was associated 
with fewer visits to the doctor, antibiotics prescriptions and reduced absence of day 
care.  
 
The significant effects were modest with difference in the number of days of illnesses 
calculated as less then 1 day in both studies and hence the clinical relevance is unclear 
and cannot be extrapolated from these studies performed over a short period of time.  
 
This study therefore aims to assess the effect of early regular supplementation of 
probiotics in the infant diet on protective benefit against diarrhoeal and febrile 
illnesses in this longitudinal study to determine if this effect is short term (6 months, 





5.2 Materials and Methods 
5.2.1 Ascertainment of infections 
 
Infants were reviewed by a paediatrician at 1, 3, 6, 12 and 24 months of age, which 
involved a detailed history, recording of anthropometric data and clinical examination. 
Questionnaires were also administered at these visits to record clinical illnesses. In 
addition, questionnaire phone surveys (Appendix D) were performed biweekly for the 
first 6 months and after which conducted at monthly intervals to document the 
incidence of infectious episodes, defined as fever more than 38.5˚C, diarrhoea lasting 
more than 3 day, upper respiratory tract infection (URTI) lasting more than 14 days, 
lower respiratory tract infection (LRTI) and wheezing, with particular emphasis on 
those that require antibiotic use of more than 3 days period, doctor visits or 
hospitalizations (Appendix B, Adverse Events Form and Serious Adverse Events 
Form). Diary charts (Appendix C) were also used by the parents to record details of 
infections to lessen recall bias.  
5.2.2 Statistical analysis 
 
All statistical analysis was carried out on an intention-to-treat approach. Incidence of 
infectious episodes were calculated and expressed as percentages. SPSS software 
(version 15.0 for Windows) was used to perform Chi-square test to compare 
differences in incidence of infectious episodes, antibiotic usage and hospitalization 
between placebo and probiotic groups. The effects of confounding factors such as 
sibling number, attendance at child care and feeding history were assessed using 
multiple logistic regression analysis and expressed as odds ratio (OR) with 95% 
confidence interval (CI). The number of antibiotic courses was logarithmically 





comparision of geometric mean. A p value of <0.05 was considered statistically 
significant for all analyses.   
 
5.3 Results 
5.3.1 Effect on Infections and Antibiotics Usage during Intervention 
period 
 
In the first 6 months of life, incidence of febrile episodes more than 38.5oC occurred 
in 16.5% of the infants in the placebo group. Only 5.8% of the subjects suffered from 
gastroenteritis more than 3 days in the placebo group. The incidences of URTI and 
LRTI were about equal at 6.6% and 5.8% respectively in the placebo group. During 
the probiotic supplementation period (0–6 months), we observed no significant 
difference between the probiotic and placebo groups in the occurrence (at least once) 
of febrile episodes more than 38.5oC (18.5% vs. 16.5%; p=0.677), gastroenteritis 
lasting more than 3 days (7.3% vs. 5.8%; p=0.640), URTI more than 14 days (4.0% vs 
6.6%; p=0.367), LRTI (5.6% vs. 5.8%; p=0.962) and wheezing (6.5% vs. 4.1%; 
p=0.418).  No difference was also found between infants who received antibiotics in 
the probiotic group (n=10/124; 8.1%) as compared to that in the placebo group 
(n=13/121; 10.7%) (p=0.472). The geometric mean number of antibiotics courses 
taken was 1.07 in the probiotic and 1.05 in the placebo group (ratio: 1.01; 95% CI: 
0.84 – 1.21; p=0.854). However interestingly, more infants were hospitalization due 
to infections in the probiotic group (n=14/124; 11.3%) than that in the placebo group 
(n=4/121; 3.3%) during the first 6 months intervention period (p=0.016) (Table 5.1). 
After adjustment with possible confounding factors such as sibling number, 
attendance at child care and feeding, the infants in the probiotic group is 3.94 times 





6 months than subjects in the placebo group. Further analysis showed that the ratio of 
hospitalization per episode of acute infections was higher in the probiotic group 
(12.0%; n=15/125) compared to only 3.6% (n=5/137) in the placebo group (p=0.018). 
The 15 subjects in the probiotic group were hospitalized due to diarrhoea more than 3 
days (n=1), fever higher than 38.5˚ C (n=1), URTI (n=1), LRTI (n=3) and other febrile 
illnesses (n=9). The 5 subjects in the placebo group were hospitalized due to fever 
higher than 38.5˚C (n=1), LRTI (n=3) and urinary tract infection (n=1) summarised in 
Table 5.2. 
 
Table 5-1 Occurrence (at least once) of infectious episodes, antibiotics use and 
hospitalization per subject between treatment groups during intervention (0-6 months) 
period 
 
 Placebo  
n = 121 (%) 
Probiotics  
n = 124 (%) 
Significance 
P 
    
Incidence of infectious episodes by 6 months     
   Febrile episode more than 38.5oC 20 (16.5) 23 (18.5) 0.677 
   Gastroenteritis lasting more than 3 days 7 (5.8) 9 (7.3) 0.640 
   URTI lasting more than 14 days 8 (6.6) 5 (4.0) 0.367 
   LRTI 7 (5.8) 7 (5.6) 0.962 
   Wheezing 5 (4.1) 8 (6.5)  0.418 
    
Incidence of antibiotics use by 6 months     
   Used antibiotics 13 (10.7) 10 (8.1)  0.472 
    
Incidence of hospitalization due to infections  
by 6 months  
4 (3.3) 14 (11.3)  0.016* 
    
 
-  8 subjects (5 placebo, 3 probiotic) without any clinical assessment after 
randomisation due to withdrawal of consent / withdrawal by investigator / lost 
to follow up were excluded 
 
 URTI  - upper respiratory tract infection  







Table 5-2 Episodes of hospitalization due to infections by 6 months in the placebo 




hospitalization due to 
infections  







Fever  > 38.5˚C 1 4 
Diarrhoea > 3 days 0 1 
URTI 0 1 
LRTI 3 3 
Urinary Tract Infection 1 3 
Viral Infection 0 2 
Erysipelas 0 1 
Total 5 15 
 
 URTI  - upper respiratory tract infection  

















5.3.2 Effect on Infections and Antibiotics Usage during Follow-up (6-24 
months)  
 
The subjects were continued to be follow-up for infectious episodes from 6 to 24 
months of age (Table 5.3). Febrile episodes more than 38.5oC occurred in about half 
of the subjects (46.3%) in the placebo group. The incidence of gastroenteritis more 
than 3 days increased to 25.6% in the follow-up period. Incidence of URTI and LRTI 
also doubled to 12.4% and 10.7% in the placebo group as compared to the first 6 
months of life. The incidence of acute infectious illnesses in the probiotic and placebo 
group, including febrile episodes more than 38.5oC (55.6% vs. 46.3%; p=0.142), 
gastroenteritis lasting more than 3 days (19.4% vs. 25.6%; p=0.239), URTI more than 
14 days (13.7% vs 12.4%; p=0.760), LRTI (7.3% vs. 10.7%; p=0.350) and wheezing 
(12.9% vs. 13.2%; p=0.940) were observed to be similar in the probiotic and placebo 
groups from 6 to 24 months of life. Recurrent wheezing episodes (≥ 2) occurred in 
9.5% of the children in the probiotic group and 10.2% in the placebo group from 6 to 
24 months (p=0.849). By 2 years of age, about half of the subjects received antibiotics 
with no significant difference between the probiotic group (46%) and the placebo 
(53.7%) group (p=0.225). The geometric mean number of antibiotics courses taken 
was 1.51 in the probiotic and 1.58 in the placebo group (ratio: 0.95; 95% CI: 0.79 – 
1.14; p=0.606). The rate of hospitalization due to infections between the probiotic 











Table 5-3 Occurrence (at least once) of infectious episodes, antibiotics use and 
hospitalization per subject between treatment groups during follow-up (>6-24 months) 
period 
 
 Placebo  
n = 121 
(%) 
Probiotics  




    
Incidence of infectious episodes, 6-24 months     
   Febrile episode more than 38.5oC 56 (46.3) 69 (55.6) 0.142 
   Gastroenteritis lasting more than 3 days 31 (25.6) 24 (19.4) 0.239 
   URTI lasting more than 14 days 15 (12.4) 17 (13.7) 0.760 
   LRTI 13 (10.7) 9 (7.3) 0.350 
   Wheezing 16 (13.2) 16 (12.9) 0.940 
       Recurrent wheeze ≥ 2 12 (9.5) 13 (10.2) 0.849 
Incidence of antibiotics use, 6-24 months     
   Used antibiotics 65 (53.7) 57 (46.0) 0.225 
    
Incidence of hospitalization due to infections,  
6-24 months  
15 (12.1) 12 (9.9) 0.496 
    
 
- 8 subjects (5 placebo, 3 probiotic) without any clinical assessment after 
randomisation due to withdrawal of consent / withdrawal by investigator / lost 


















Probiotics may influence the incidence of infections by enhancing humoral and 
cellular immunity [254]. Several studies have been published on the preventive effect 
of probiotics on infectious illnesses in infants and children [168, 175, 176, 178, 255-
257]. We aimed to evaluate the effects of probiotics on the type, frequency and 
severity of acute infectious illnesses in infants. Short term (intervention period, 0-6 
months) and long term effects in a 2 years follow-up period were investigated. This 
study did not to demonstrate any protective effect of probiotic supplementation on 
infection. Rates of febrile episodes, gastroenteritis and respiratory infections were 
similar in both groups during the intervention and follow-up period. The rate of 
antibiotic usage and number of courses were also similar between the two groups. 
Interestingly, more infants were hospitalization for infections by 6 months in the 
probiotic group than in the placebo group (ORadj: 3.94; 95% CI = 1.21 to 12.75, 
p=0.022). This difference was not observed later during the follow-up period.  
 
These findings contrast with many previous studies demonstrating that probiotic 
agents are able to prevent or treat gastrointestinal infections, particularly those of viral 
etiology [258-260]. The study in Israeli infants in child care centre demonstrated 
decreased febrile episodes and diarrhoea episodes in infants supplemented with L. 
reuteri or B. lactis. In particular, L. reuteri supplementation decreased antibiotic 
prescriptions. But similar to our study, probiotic supplementation had no effect on 
respiratory illness [176]. The difference in outcomes may be explained by the higher 
incidence of gastrointestinal infections in Israel. The Swedish study by Abrahamsson 
et al. [169] with the primary aim to evalutate the prevention of eczema with 





but found no effect on gastroenteritis with 30% in the placebo group and 29% in the 
probiotic group by 1 year of age. In comparision, our study showed a lower incidence 
of 15.7% of gastroenteritis lasting more than 3 days in the first 12 months of life in 
the placebo group. This lack of protection in communities with low prevalence of 
diarrhoea illness has also been demonstrated in other studies. These include 2 Finnish 
studies among children in day care, one using L. rhamnosus GG [175], and another by 
Kukkonen et al. [178] where supplementation of synbiotics were used.  On the other 
hand, the Australian eczema prevention study study (Taylor et al.) which used L. 
acidophilus supplementation for the first 6 months of life found significantly fewer 
gastrointestinal infections from 1-2.5 years of age (12%) compared with the placebo 
(27%) group (p = 0.023) [168]. This difference was observed only after the 1st year of 
life at the 2.5 years follow-up analysis [167]. Taylor et al. also demonstrated no 
protective effect of L. acidophilus supplementation on respiratory tract infections and 
paradoxically showed a greater frequency of wheeze in the first 6 months of life [167]. 
This finding corresponded with the data from another German study on the prevention 
of eczema where a significantly higher proportion of L. rhamnosus GG supplemented 
children with recurrent (≥5 episodes) wheezing bronchitis was observed compared to 
placebo in the first 2 years of life [171]. Infants who are genetically at risk for atopy 
have been proposed to have compromised resistance to respiratory infections [261].  
 
Our results did not demonstrate a reduction in the rate of antibiotic use with probiotic 
supplementation. Moreover, a significantly higher proportion of children in the 
probiotic group were hospitalized due to infections during the first 6 months of life 
suggesting more severe infections. Adjustment with sibling number, attendance at 





line with Taylor et al.’s study in which a higher rate of antibiotic use in the probiotic 
group, particularly in the first 6 months during L. acidophilus supplementation [167]. 
This trend is similarly shown by Abrahamsson et al. as antibiotics were more 
frequently prescribed in the L. reuteri group during the first year of life [169]. Rate of 
hospitalization was not assessed in these studies but the higher rate of antibiotics used 
similarly suggest more severe infections in the probiotic group. 
 
There is currently insufficient evidence to advocate the use of probiotics for the 
prevention of common acute childhood infections. Although accumulating data 
suggest that these organisms may help prevent both respiratory and diarrhoeal 
diseases in children at increased risk of such infections, such as those in day care 
facilities or living in developing countries, it is probable that in our study, the cohort 
of infants being examined is generally healthy and this study was conducted in a 
developed community where infant nutrition is optimal with diligent hygiene practise, 
and hence the effect of probiotics on preventing acute infections was not discernable.  
 
However, the concerning increase in the rate of hospitalization during probiotic 
supplementation period could be of importance in view of the wide availability of 
probiotics in infant formula. It is inappropriate to recommend probiotics for 
prevention of childhood acute infections in Singapore until more studies in 
communities unravel the role and complexities of interaction between the early 






6 Chapter 6:                                                                      




Nutrition is the main determinant of childhood growth during the first few years of 
life. Infants receiving formulas with probiotics can have an impact on their growth 
during the supplementation and also in the long term. Probiotics may alter the 
gastrointestinal flora and contribute to the host’s energy metabolism which enhances 
the uptake of nutrients to increase nutritional status and improve physical growth. In a 
double-blind, randomized study, healthy term infants who received L. rhamnosus GG-
supplemented formula for 6 months grew to a significantly higher length and weight 
than the infants who received regular formula [189]. Other studies observed similar 
normal growth in both probiotic-treated and placebo study groups [177, 178, 190, 
191, 262]. Safety and tolerance of infant formulas supplemented with probiotics needs 
to be further evaluated to assess the possible influence of these microorganisms on 
growth in early infancy. We therefore aim to document safety and impact on growth 
of newborn infants in this study during the 6 months intervention and 2 year follow-











6.2 Materials and Methods 
6.2.1 Growth measurements 
 
Infants were reviewed by a neonatologist at birth and a paediatrician at 1, 3, 6, 12 and 
24 months of age, which involved a detailed history, recording of anthropometric data 
and clinical examination. Weight and length measurements were made according to 
standardized techniques by using an infant stadiometer (length board) and calibrated 
infant electronic scale. The Body Mass Index (BMI) was calculated as the ratio of 
weight (in kg)/recumbent length or standing height (in m2). The occipitofrontal head 
circumference (OFC) of subjects was measured to the nearest 2mm with standard 
measuring tapes. 
 
6.2.2 Statistical analysis 
 
Data analysis was conducted by using SPSS software (version 15.0 for Windows).  
Means plus/minus (±) standard deviation of the anthropometric measures of infants in 
the placebo and probiotic groups, who were followed up to 1, 3, 6, 12 and 24 months 
were calculated and analyzed by using the Student’s t-test for independent samples. 
Changes in weight (weight gain), recumbent length / height, Body Mass Index (BMI) 
(weight/height2), and OFC from birth to 24 months were analyzed by a mixed model 
correcting for gender and feeding history. The mixed model describes the 
development of growth parameters over time by a quadratic curve, taking into account 
each subject’s intercept and slope (random effects) and is robust against dropouts 
[263]. Weight-for-age, length-for-age, head-circumference-for-age and BMI-for-age 
z-scores (also called standard deviation scores - SDS) were calculated based on the 





years old in any country, regardless of ethnicity [264]. A p value of <0.05 was 




The anthropometric measures of weight (kg), length (cm), BMI (kg/m2) and OFC (cm) 
at birth and 1, 3, 6, 12 and 24 months old showed similar normal growth in the 
probiotic and placebo groups (Table 6.1 and Table 6.2). No differences in birth weight 
(3.15 ± 0.45 and 3.14 ± 0.42 kg; p=0.775) and length (49.62 ± 2.32 and 49.76 ± 2.78 
cm; p=0.656) were observed between the probiotic and placebo group. A comparison 
of weight, length and BMI z-scores with the WHO Child Growth Standards showed 
that the mean z-scores of infants in both the probiotic and placebo group were close to 
0 at all times during the study (Figure 6.1, 6.2 and 6.3).  
 
The infants in the probiotic group had a higher weight for age z-scores (Means ± SD) 
from 1 to 24 months of age (Figure 6.1), particularly at one time point of 6 months old 
(0.18 ± 0.89) compared to the placebo group (-0.02 ± 1.05), this difference was not 
significant (p = 0.089) and the z-scores were comparable at other time points (Table 
6.2). Weight gain (z-scores) during the treatment and follow-up period were similar 
among infants in the different formula groups. Growth in weight, expressed in z-
scores, was particularly higher in the probiotic group (0.00 ± 0.67) than the placebo 
group (-0.15 ± 0.68) between 1 to 3 months and this difference was near to significant 
(p = 0.072) (Table 6.3). There were no significant differences in subjects’ weight 
changes associated with treatment between probiotic and placebo groups from birth to 
24 months of age (F = 2.474, p= 0.117) with adjustment for gender and feeding 





differences were also found for change in mean length (probiotics vs. placebo; F = 
0.044, p= 0.835) and OFC (probiotics vs. placebo; F = 0.271, p= 0.603). Mean 
changes in length, OFC, and BMI z-scores during the treatment period were not 
different between the probiotic and placebo group (Table 6.3 and 6.4). 
The curve of the probiotic group showed consistently higher BMI than that among the 
subjects in the placebo group from birth to 24 months of age (Figure 6.4). Mean 
differences in BMI between probiotic and placebo groups (F=3.359, p=0.068) with 
adjustment for gender and feeding history (during the first 6 months intervention 
period) using mixed model repeated measures analysis showed a near to significance 




In this longitudinal study we evaluated the safety of infant formula supplemented with 
B. longum and L. rhamnosus LPR in normal healthy term infants. The outcomes of 
weight gain, changes in length, head circumference and BMI after 6 months of 
intervention were similar in the probiotic and placebo groups. In addition, the long 
term follow-up to 2 years of age found no significant difference between the weight, 
length/height, head circumference and BMI of the two treatment groups. During both 
periods infants in both groups grew normally as the weight-for-age, length-for-age, 
BMI-for-age and head circumference z-scores indicated growth rates comparable to 
the WHO Child Growth Standards. These are good indications of the nutritional 
sufficiency and adequate growth of both the probiotic-supplemented and normal 
cow’s milk based formulas fed subjects in our study as these standards are based on 






Although not statistically significant, the BMI between the placebo and probiotics 
supplemented groups revealed that the probiotics group demonstrated higher BMI 
compared to the placebo group consistently to 24 months of age even though the BMI 
at birth were similar (Figure 6.4). The BMI for age z-score in the probiotic group was 
closer to zero (the expected value for the reference distribution) from 3 to 12 months 
of age, indicating better growth status as WHO proposed the Child Growth Standards 
to be a standard for normal growth in infancy applicable throughout the world [264]. 
This is consistent with the study by Vendt et al. [189] which reported more weight 
gain, expressed in age-adjusted SDS (z-scores), at 3 months and better growth in 
length and weight at 6 months of age in the probiotic group compared with the 
placebo. BMI was not analysed in this study. Therefore the difference in BMI in our 
study suggests that there might be a difference in the effect of the probiotic-
supplemented and placebo formula. Our results might not have been sufficiently 
powered to detect the difference as this was not a primary aim of the study and the 
limitations of these data are recognized. 
 
Other studies observed similar normal growth in both probiotic-treated and placebo 
study groups. In a study in the United States, growth was similar in infants who 
received a standard milk-based formula containing B. lactis and Streptococcus 
thermophilus or unsupplemented formula [177]. Although, the change in z scores of 
weight, height and weight/length during the study period (210 ± 127 days) were not 
significantly different between the groups, the growth trend over the supplementation 
period was not analysed as only 2 data sets at entry and at discharge were reported.  
Another study in France concluded that infants fed a mixture of probiotics or 





BMI measurements compared with those fed a control formula [190]. In spite of this, 
the higher z-scores for length at 12 months in the B. longum and L. rhamnosus LPR 
group suggested a possible effect of the probiotics compared with the control. 
However, the study was not designed with sufficient sample size to detect this 
difference. Furthermore, all of the comparisons in weight gain between treatment and 
control showed a trend toward better weight gain in the probiotics and synbiotics 
group. Similarly, the authors suggested a bigger sample size in future studies to see a 
difference in weight-for-age z-scores.  
 
Probiotics may alter the gastrointestinal flora where different composition of gut 
microbiota may have direct action on the villous epithelium and determine differences 
in the efficiency of caloric extraction from food for energy storage [265]. Ley et al. 
[266] reported that obese human subjects have relatively less Bacteroides and more 
Firmicutes in the stools compared to lean human subjects. This was also confirmed in 
the study of gut microbiota of lean and obese mice where genetically obese mice had 
half the abundance of Bacteroidetes and higher proportion of intestinal Firmicutes 
compared to their lean siblings [267]. In another animal study, microbiota of obese 
and lean mice was transferred to lean germ-free recipient mice, and over a two week 
period, mice colonized with the microbiota from obese mice had significantly greater 
increase in total body fat than that of mice colonized by microbiota from lean mice 
[268].  Kalliomaki et al. study, with the primary aim to evaluate prevention of allergy 
with probiotic supplementation from birth, reported lower bifidobacteria and higher 
Staphylococcus aureus in the stools at 6 and 12 months of age being associated with 






Serial stool samples at 3 days, 1 month, 3 months, and 1 year were also collected from 
the subjects in our study.  Stool microbiota analysis of 37 consecutive subjects with 
(n= 20) or without (n= 17) probiotic administration were reported recently [229]. The 
probiotics B. longum (p=0.005) and L. rhamnosus (p <0.001) were detected more 
frequently in probiotic subjects during supplementation, but no difference were found 
after the probiotic-supplemented formula intervention had stopped. More colony-
forming units of lactic acid bacteria were also cultured in the stools of probiotic-
supplemented babies at month 3 during treatment period (p=0.035). Transient 
alteration of gut flora in early life through probiotic supplementation can possibly 
results in programming and alteration of subsequent growth trajectory and adiposity 
gain.  
 
Breastfed infants are generally healthier than formula-fed infants as breast milk is an 
optimal source of nutrition with complex oligosaccharides to selectively stimulate the 
growth of beneficial bacteria and inhibit the growth of pathogens [270]. In our study, 
feeding history did not differ between the study groups. At the end of the 6 months 
supplementation period, only 2% in the placebo and 3% in the probiotic group had 
near total breastfeeding with at least 60ml of trial formula. Majority of the subjects 
had some breastfeeding combined with formula feeding (77% in placebo and 65% in 
probiotic group) (Refer to Table 3.5 in Chapter 3). Introduction of solid food did not 
differ between the two groups. All subjects had been weaned to semi-solids by 12 
months and the median age of weaning was 6 months for both groups (Refer to Table 
3.6 in Chapter 3). All but one or two subjects in each group had egg yolk, egg white, 
fish and soy products and about 87% in the placebo group and 83% in the probiotics 





therefore comparable and should not have influenced the difference in growth 
significantly 
 
This study confirms the adequate growth and safety in healthy probiotic supplemented 
infants. It also raises the possibility that probiotic supplementation leads to better 
growth which is closer to the WHO standards. This finding needs to be confirmed on 
longer follow-up as it can have significant impact on clinical practice and 
recommendations and also provides strong evidence for the influence of gut 







Table 6-1 The growth characteristics (mean ± SD) of the study population (from birth to 3 months) with two-sample t-test for comparison 

































Length(cm) 49.76±2.78 49.62±2.32 0.656 54.55±2.55 54.22±2.60 0.316 61.40±2.85 61.36±2.62 0.908 
Length  
z-scores 
0.16±1.24 0.06±1.23 0.515 0.16±1.23 0.04±1.26 0.456 0.33±1.27 0.38±1.24 0.752 
Weight (kg) 3.14±0.42 3.15±0.45 0.775 4.45±0.55 4.43±0.55 0.694 6.19±0.83 6.26±0.69 0.520 
Weight  
z-scores 
-0.37±0.92 -0.31±0.99 0.641 0.16±0.86 0.16±0.90 0.984 -0.21±1.11 -0.03±1.16 0.157 
BMI (kg/m2) 12.70±1.72 12.79±1.31 0.651 14.97±1.28 15.05±1.33 0.644 16.39±1.54 16.63±1.51 0.234 
BMI  
z-scores 
-0.69±1.00 -0.53±1.12 0.231 0.13±0.92 0.20±0.98 0.540 -0.23±1.03 -0.03±1.02 0.139 
OFC 
(cm) 
33.42±1.97 33.34±1.41 0.715 37.23±1.34 37.18±1.36 0.795 40.09±1.48 40.08±1.29 0.950 
OFC 
z-scores 







Table 6-2 The growth characteristics (mean ± SD) of the study population (from 6 to 24 months) with two-sample t-test for comparison between 

































Length(cm) 67.50±2.90 67.88±2.82 0.317 76.25±3.84 76.31±3.15 0.890 87.34±3.98 87.07±3.90 0.611 
Length  
z-scores 
0.31±1.20 0.48±1.13 0.276 0.51±1.47 0.53±1.15 0.923 0.25±1.23 0.20±1.29 0.752 
Weight (kg) 7.69±1.01 7.82±0.877 0.299 9.41±1.21 9.56±1.16 0.347 12.14±1.76 12.38±2.11 0.358 
Weight  
z-scores 
-0.02±1.05 0.18±0.89 0.089 0.00±1.06 0.18±1.00 0.178 0.10±1.15 0.18±1.05 0.572 
BMI (kg/m2) 16.83±1.57 16.94±1.32 0.533 16.16±1.44 16.39±1.44 0.226 15.89±1.80 16.32±2.30 0.123 
BMI  
z-scores 
-0.27±1.05 -0.15±0.88 0.342 -0.34±1.01 -0.19±1.03 0.259 -0.09±1.33 0.11±1.36 0.239 
OFC 
(cm) 
42.64±1.58 42.73±1.47 0.668 45.78±1.54 45.96±1.50 0.358 48.40±1.59 48.26±1.37 0.495 
OFC 
z-scores 





Figure 6-1 Weight for age z-scores (Means ± SD), relative to WHO standards, during 












































Figure 6-2 Length / Height for age z-scores (Means ± SD), relative to WHO 
standards, during intervention period to 6 months and follow-up period up to 24 











































Figure 6-3 BMI (kg/m2) for age z-scores (Means ± SD), relative to WHO standards, 















































Figure 6-4 BMI (kg/m2), Means ± SD, during intervention period to 6 months and 































* Mean differences in BMI between treatment groups from birth to 24 months of age 
(F=3.359, p=0.068) with adjustment for gender and feeding history (first 6 months) 





Table 6-3  Mean (±SD) weight gain and changes in length, head circumference, and body mass index (BMI) for age and gender z-scores from 





(mean ± SD) 
 






































0.01 ± 1.01 -0.42 ± 1.07 0.670 0.14 ± 1.02 0.31 ± 1.27 0.244 -0.11 ± 0.87 0.14 ± 1.30 0.300 
Weight (kg) 
z-scores 
0.51 ± 0.65 0.46 ± 0.59 0.498 -0.15 ± 0.68 0.00 ± 0.67 0.072 -0.05 ± 0.46 0.01 ± 0.57 0.292 
BMI (kg/m2) 
z-scores 
0.79 ± 1.02 0.72 ± 1.13 0.606 -0.34 ± 1.04 -0.24 ± 1.04 0.475 -0.07 ± 0.72 -0.11 ± 0.95 0.724 
OFC(cm)  
z-scores 





Table 6-4  Mean (±SD) weight gain and changes in length, head circumference, and body mass index (BMI) for age and gender z-scores from 6 





(mean ± SD) 
 

























0.16 ± 1.25 0.04 ± 1.07 0.443 -0.23 ± 1.11 -0.33 ± 1.18 0.509 
Weight (kg) 
z-scores 
0.00 ± 0.71 -0.005 ± 0.56 0.944 0.09 ± 0.81 0.06 ± 0.66 0.727 
BMI (kg/m2) 
z-scores 
-0.08 ± 1.12 -0.05 ± 0.96 0.834 0.21 ± 1.28 0.35 ± 1.26 0.432 
OFC(cm)  
z-scores 





7 Chapter 7:  Conclusions and Future Directions 
 
Several specific aims were achieved in this dissertation: 1) to assess the effect of 
administration of Bifidobacterium longum and Lactobacillus rhamnosus 
supplemented cow’s milk based infant formula from birth to 6 months on the 
prevention of allergic diseases, namely eczema, asthma, allergic rhinitis, and allergic 
sensitization in the first and second year of life among Asian infants at risk of allergic 
disease; 2) to investigate the effect of probiotic supplementation in the first 6 months 
of life on specific IgG antibody responses to Hepatitis B vaccination; 3) to determine 
the short and long term effect of early regular supplementation of probiotics in the 
infant diet on protective benefit against diarrhoeal and febrile illnesses; and 4) to 
document safety and impact on growth of newborn infants in this study with a 2 years 
follow-up period. 
 
This double-blind, randomized, placebo controlled clinical trial on the 
supplementation of probiotics in the first six months of life in Asian infants at risk of 
allergic diseases did not show a protective effect of probiotic supplementation on 
eczema, asthma, allergic rhinitis or allergen sensitization at 1 and 2 years of age. 
Subset analysis of interactions between mode of delivery and probiotic intervention 
did not show a significant difference in prevalence of eczema, allergen sensitization 
and atopic eczema in caesarean-delivered babies supplemented with probiotics. The 
prevalence of eczema in our cohort (26%) was lower than the 39% in the placebo 
group at 1 year and 46% at 2 years in the other studies in Australia and Finland. An 
additional follow-up period will be critical for the evaluation of respiratory allergies 
as the low prevalence of 9% asthma and 2.5% allergic rhinitis at 2 years of age did not 





dose and probiotic strain are used in various studies, additional studies need to be 
conducted to ascertain how probiotics exert their effects on allergic diseases.  
 
Family history and elevated cord blood serum IgE were not found to influence the 
development of eczema, allergen sensitization, atopic eczema at 1 year of age. 
Parental atopy in combination with elevated cord IgE also fails to identify babies at 
risk of eczema and allergen sensitization. Paternal eczema was instead significantly 
associated while maternal atopy and mothers with eczema were not found to be a risk 
factor for eczema.  
 
In the determination of the effects of probiotic supplementation to enhance the 
immunogenicity of Hepatitis B vaccine responses, our results show that the schedule 
with 3 monovalent doses of Hepatitis B vaccine resulted in better anti-HBs responses 
compared to the schedule consisting of 2 monovalent doses followed by a third dose 
as a DTPa combination vaccine, although this difference was not statistically different. 
Probiotics can potentially be used as an adjuvant to enhance immune responses in 
schedules with less than optimal responses, but these findings need to be explored in 
studies with larger sample size.  
 
The effects of probiotics supplementation on protective benefit against acute 
infectious illnesses in infants were not demonstated in our study. Rates of febrile 
episodes, gastroenteritis and respiratory infections were similar in the probiotic and 
placebo groups during the intervention and follow-up period. Antibiotic usage and 
courses were also similar between the two groups. To note, more infants were 





than in the placebo group but this difference was not observed later during the follow-
up period. Although probiotics did not prevent common childhood infections, no 
adverse events related to the study formula was observed. However, it raises the 
possibility of increased hospitalization during probiotic supplementation period which 
needs to be further determined in more controlled clinical studies to confirm the 
safety of the administration of Bifidobacterium longum and Lactobacillus rhamnosus 
from birth. 
 
In order to evaluate the safety of the probiotic formula in early infancy, we assessed 
the possible influence of these probiotics on growth. The outcomes of weight gain, 
changes in length, head circumference and BMI were similar in the probiotic and 
placebo groups during the intervention and long term follow-up period to 2 years of 
age. Adequate growth was observed during both periods in the 2 groups as the 
weight-for-age, length-for-age, BMI-for-age and head circumference z-scores 
indicated normal growth rates. Notably, the BMI between the placebo and probiotics 
supplemented groups revealed that the probiotics group had higher BMI compared to 
the placebo group consistently to 24 months of age even though the BMI at birth were 
similar. This difference in trend was near to significance. This study confirms that the 
supplementation of probiotics from birth yielded adequate growth similar to the 
infants in the placebo group. Despite appearing to be safe for newborn infants, 
probiotic supplementation can possibly leads to increase growth which needs to be 
confirmed on longer follow up.  
 
In conclusion, the findings can have significant impact on clinical practice and 





interaction of specific strains of probiotics and the developing immune system before 
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